Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Cardiac Applications of Positron Emission Tomography (PET) Scanning are considered in medical policy 00103.

Note: Miscellaneous Applications of Positron Emission Tomography (PET) Scanning are considered in medical policy 00104.

Note: Interim Positron Emission Tomography Scanning in Oncology to Detect Early Response During Treatment is addressed separately in medical policy 00590.

Note: This policy only addresses the use of radiotracers detected with the use of dedicated PET scanners. Radiotracers such as fluorodeoxyglucose (FDG) may be detected using single photon emission computed tomography (SPECT) cameras, a hybrid PET/SPECT procedure that may be referred to as FDG-SPECT or molecular coincidence.

For this policy, PET scanning is discussed for the following four applications in oncology:

- **Diagnosis.** Diagnosis refers to use of positron emission tomography (PET) as part of the testing used in establishing whether or not a patient has cancer.

- **Staging.** This refers to use of positron emission tomography (PET) to determine the stage (extent) of the cancer at the time of diagnosis, before any treatment is given. Imaging at this time is generally to determine whether or not the cancer is localized. This may also be referred to as initial staging.

- **Restaging.** This refers to imaging following treatment in two situations. Restaging is part of the evaluation of a patient in whom a disease recurrence is suspected based on signs and/or symptoms. Restaging also includes determining the extent of malignancy following completion of a full course of treatment.

- **Surveillance.** This refers to use of imaging in asymptomatic patients (patients without objective signs or symptoms of recurrent disease). This imaging is completed 6 months or more (12 months or more for lymphoma) following completion of treatment.

**Coverage Eligibility**
The following apply to the listed oncologic applications of positron emission tomography (PET) scanning:

- **Eligible for Coverage**
  Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:
  - Benefits are available in the member’s contract/certificate, and

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

- Medical necessity criteria and guidelines are met.

**Investigational**
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

All policy statements apply to both positron emission tomography (PET) scans and positron emission tomography (PET) plus computed tomography (CT) scans, i.e., positron emission tomography (PET) scans with or without positron emission tomography/computed tomography (PET/CT) fusion.

For the clinical situations indicated that may be considered medically necessary, this assumes that the results of the positron emission tomography (PET) scan will influence treatment decisions. If the results will not influence treatment decisions, these situations would be considered investigational.

Based on review of available data, the Company considers the use of positron emission tomography (PET) scans for oncology applications to be either eligible for coverage** or investigational* as indicated below:

**Anal Cancer**

**Eligible for Coverage**

*Staging* When used in the staging of anal cancer when CT of chest, abdomen, and pelvis are equivocal or non-diagnostic for metastatic disease, positron emission tomography (PET) may be eligible for coverage.**

When used for radiation planning (when radiation treatment is indicated), positron emission tomography (PET) may be eligible for coverage.**

*Restaging* When used in the restaging of anal cancer when CT of chest, abdomen, and pelvis are equivocal or non-diagnostic for metastatic disease, positron emission tomography (PET) may be eligible for coverage.**

When used in the restaging of local recurrence when salvage surgery is planned, positron emission tomography (PET) may be eligible for coverage.**

**Investigational**

When used for all other indications (other than described above), positron emission tomography (PET) is considered to be investigational. *

**Bladder Cancer**

**Eligible for Coverage**

*Staging* When used in the staging of muscle-invasive bladder cancer when CT or magnetic resonance imaging are not indicated or remained inconclusive on distant metastasis, positron emission tomography (PET) may be eligible for coverage.**

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Restaging
When used in the restaging of muscle-invasive bladder cancer when CT or magnetic resonance imaging are not indicated or remained inconclusive on distant metastasis, positron emission tomography (PET) may be eligible for coverage.**

Investigational
When used for bladder tumors that have not invaded the muscle (stage <cT2) and for all other indications (other than described above), positron emission tomography (PET) is considered to be investigational.*

Bone and Soft Tissue Sarcoma

Eligible for Coverage

Staging
When used in the staging positron emission tomography (PET) scanning may be eligible for coverage** in ANY of the following scenarios (all tumor types):
  o When standard imaging studies (e.g., CT or MRI) are equivocal or non-diagnostic for metastatic disease; OR
  o When standard imaging suggests a resectable solitary metastasis; OR
  o As a baseline study prior to neoadjuvant chemotherapy for deep tumors larger than 3 cm

Restaging
When used in the restaging positron emission tomography (PET) scanning may be eligible for coverage** in the following scenario (all tumor types):
  o Following completion of neoadjuvant chemotherapy for deep lesions larger than 3 cm.

When used in the restaging positron emission tomography (PET) scanning may be eligible for coverage** for evaluating response to imatinib and other treatments for gastrointestinal stromal tumors.

Investigational
Staging
For all other indications (other than described above) positron emission tomography (PET) scanning is considered investigational.*

Note: Advanced imaging is considered medically necessary for staging and restaging of biopsy-proven bone, cartilage, connective tissue, and other soft tissue sarcomas.

Brain and Spinal Cord Malignancy

Eligible for Coverage

Staging
When used for staging of primary central nervous system cancer, positron emission tomography (PET) scanning may be eligible for coverage.**

Restaging
When used for restaging of primary central nervous system (CNS) cancer to differentiate post-treatment scarring from residual or recurrent disease, positron emission tomography (PET) scanning may be eligible for coverage.**
Positron Emission Tomography (PET) Oncology Applications

Policy #  00105
Original Effective Date:  01/28/2002
Current Effective Date:  06/01/2019

**Investigational**

*Diagnosis*  When used for initial diagnosis and for all other indications (other than described above), positron emission tomography (PET) scanning is considered *investigational.*

*Note:* Advanced imaging for spinal cord malignancy is indicated for spinal ependymoma, medulloblastoma, primary spinal cord tumors, leptomeningeal disease, and symptomatic or cerebrospinal fluid-positive primary CNS lymphoma.

**Breast Cancer**

*Eligible for coverage*

*Staging*  When used in the staging of breast cancer positron emission tomography (PET) scanning may be eligible for coverage** for the following application:

- Detecting locoregional or distant recurrence or metastasis (except axillary lymph nodes) when suspicion of disease is high and other imaging (e.g. CT, MRI, bone scan) is inconclusive.

*Restaging*  When used in restaging breast cancer positron emission tomography (PET) scanning may be eligible for coverage** for the following application:

- Detecting locoregional or distant recurrence or metastasis (except axillary lymph nodes) when suspicion of disease is high and other imaging (e.g. CT, MRI, bone scan) is inconclusive.

**Investigational**

All other applications of positron emission tomography (PET) scans in the evaluation of breast cancer are considered *investigational* including, but not limited to, the following:

- Differential diagnosis in patients with suspicious lesions or an indeterminate/low suspicion finding on mammography;
- Staging axillary lymph nodes;
- Predicting pathologic response to neoadjuvant therapy for locally advanced disease.

**Cervical Cancer**

*Eligible for Coverage*

*Staging*  When used in the staging of patients with locally advanced cervical cancer (i.e., stage IB2 or higher) positron emission tomography (PET) scans may be eligible for coverage.**

*Restaging*  When used in the restaging of cervical cancer and in the evaluation of known or suspected recurrence or progressive disease especially when standard imaging is equivocal or non-diagnostic, positron emission tomography (PET) scans may be eligible for coverage.**
**Positron Emission Tomography (PET) Oncology Applications**

**Policy # 00105**

**Original Effective Date: 01/28/2002**

**Current Effective Date: 06/01/2019**

---

**Colorectal Cancer**

**Eligible for Coverage**

**Staging** When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be **eligible for coverage**:  
- To detect and assess resectability of hepatic or extrahepatic metastases of colorectal cancer (CRC).
- Cancer stage remains in doubt after completion of a standard diagnostic workup and clinical management would differ depending on the stage.
- Positron emission tomography (PET) could potentially replace one or more conventional imaging studies, in patients who cannot undergo contrast-enhanced CT due to contrast allergy or renal disease especially if the patient has potentially curable disease.

**Restaging** When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be **eligible for coverage**:  
- To detect and assess resectability of hepatic or extrahepatic metastases of colorectal cancer (CRC).
- To detect residual disease (after completion of treatment).
- To detect suspected recurrence (example: rising and persistently elevated carcinoembryonic antigen [CEA] levels; clinical signs/symptoms suspicious for recurrence) when standard imaging, including CT scan with contrast, is negative or contraindicated and cancer stage remains in doubt.
- To determine the extent of known recurrence.

---

**Endometrial (Uterine) Cancer**

**Eligible for Coverage**

**Staging** Positron emission tomography (PET) scanning may be **eligible for coverage** in the:  
- Detection of lymph node metastases when standard imaging studies (CT or MRI as clinically indicated) are equivocal or non-diagnostic for metastatic disease.

**Restaging** When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be **eligible for coverage**:  
- A technique to assess the presence of scarring versus local bowel recurrence in patients with previously resected colorectal cancer (CRC).
- A technique contributing to radiotherapy treatment planning.

---

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 5 of 64
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Esophageal and Gastroesophageal Junction Cancer

**Eligible for Coverage**

**Diagnosis**
When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be eligible for coverage**:
- To avoid an invasive diagnostic procedure.
- To determine the optimal anatomical location to perform an invasive diagnostic procedure.

**Staging**
When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be eligible for coverage**:
- Staging of esophageal cancer especially when standard imaging has been performed and has not demonstrated metastatic disease or remained inconclusive.

**Restaging**
When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be eligible for coverage**:
- Restaging after the completion of definitive treatment (chemoradiation) or to determine response to preoperative induction therapy.
- Detection of residual disease, suspected recurrence (based on signs or symptoms), or to determine the extent of a known recurrence when standard modalities are equivocal for recurrent disease.

**Investigational**

**Diagnosis**
When used in the evaluation and detection of primary esophageal cancer positron emission tomography (PET) scanning is considered investigational.*

Gastric Cancer

**Eligible for Coverage**

**Diagnosis**
When positron emission tomography (PET) results may assist in the following situation positron emission tomography (PET) scanning may be eligible for coverage**:
- Initial diagnosis of gastric cancer.

**Staging**
When positron emission tomography (PET) results may assist in the following situation positron emission tomography (PET) scanning may be eligible for coverage**:
- Initial staging of gastric cancer.

**Restaging**
Evaluation for recurrent gastric cancer after surgical resection, when other imaging modalities are inconclusive may be eligible for coverage.**
Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Positron Emission Tomography (PET) Oncology Applications

Head and Neck Cancers (excluding CNS and Thyroid)

**Eligible for Coverage**

**Diagnosis**
When positron emission tomography (PET) results may assist in the following situation positron emission tomography (PET) scanning may be eligible for coverage**:
- In the evaluation of head and neck cancer in the initial diagnosis of suspected cancer.

**Staging**
When positron emission tomography (PET) results may assist in the following situation positron emission tomography (PET) scanning may be eligible for coverage**:
- In the evaluation of head and neck cancer in the initial staging of disease.

**Restaging**
When positron emission tomography (PET) results may assist in the following situation positron emission tomography (PET) scanning may be eligible for coverage**:
- In the evaluation of head and neck cancer in the restaging of residual or recurrent disease during follow-up; and
- In the evaluation of response to treatment.

**Investigational**
When used for applications not discussed above, positron emission tomography (PET) scanning for the evaluation of head and neck cancer is considered investigational*.

Kidney Cancer/Renal Cell Carcinoma

**Eligible for Coverage**

**Staging**
When used in the staging of kidney cancer positron emission tomography (PET) scanning may be eligible for coverage** for the following application:
- To evaluate extent of disease when curative resection of primary tumor or limited metastatic disease is planned and standard imaging (e.g., CT chest, abdomen and/or pelvis, and/or MRI of brain if indicated) is equivocal for additional sites of disease.

**Restaging**
When used in restaging of kidney cancer positron emission tomography (PET) scanning may be eligible for coverage** when ALL of the following are true:
- Standard imaging studies (e.g., CT abdomen and/or pelvis) are equivocal or non-diagnostic for metastatic disease; AND
- Biopsy cannot be performed; AND
- Tumor has been shown to be PET avid (if a prior PET scan has been performed).

**Investigational**
All other applications of positron emission tomography (PET) scans in the evaluation of kidney cancer are considered investigational*.
Lung Cancer/Solitary Pulmonary Nodule

Eligible for Coverage

Diagnosis

When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be eligible for coverage**: 

- Solitary Pulmonary Nodule - In patients with a solitary pulmonary nodule to distinguish between benign and malignant disease when prior CT and chest x-ray findings are inconclusive or discordant. 
- Lung Cancer - To determine resectability for patients with a presumed solitary metastatic lesion from lung cancer. 

Staging

When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be eligible for coverage**: 

- As staging technique in those with known non-small cell lung cancer (NSCLC); or 
- In the staging of small-cell lung cancer (SCLC) if limited stage is suspected based on standard imaging. 

Note: 
Limited stage SCLC is limited to the ipsilateral hemithorax and regional or mediastinal lymph nodes and can be encompassed in a safe radiotherapy field. 

Restaging

When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be eligible for coverage**: 

- For the purpose of detecting suspected recurrence. 
- To determine the extent of a known recurrence in patients with known non-small cell lung cancer (NSCLC). 

Investigational

Staging

When used in the staging of small-cell lung cancer (SCLC) if extensive stage is established and in all other aspects of managing small-cell lung cancer, positron emission tomography (PET) scanning is investigational.*
Positron Emission Tomography (PET) Oncology Applications

Policy #  00105
Original Effective Date:  01/28/2002
Current Effective Date:  06/01/2019

- to determine the extent of a known recurrence.
- For restaging after the completion of treatment.

**Investigational**
When used for applications not discussed above, positron emission tomography (PET) scanning for the evaluation of lymphoma is considered **investigational**.

**Melanoma Eligible for Coverage**

**Staging**
When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be **eligible for coverage**:
- As a technique for assessing extranodal spread of malignant melanoma at initial staging for advanced disease (stage III or IV).

**Restaging**
When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be **eligible for coverage**:
- As a technique for assessing extranodal spread of malignant melanoma at restaging during follow-up treatment for advanced disease (stage III or IV).

**Investigational**
When used for applications not discussed above positron emission tomography (PET) scanning for the evaluation of melanoma is considered **investigational**.

Positron emission tomography (PET) scanning is considered **investigational** as a technique to detect regional lymph node metastases in patients with clinically localized melanoma who are candidates to undergo sentinel node biopsy.

Positron emission tomography (PET) scanning is considered **investigational** in managing stage 0, I, or II melanoma.

**Merkel Cell Carcinoma Eligible for Coverage**

**Staging**
When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be **eligible for coverage**:
- For initial staging of biopsy-proven Merkel cell carcinoma in clinical situations in which the stage of the cancer remains in doubt after completion of a standard diagnostic workup (e.g., CT and MRI as clinically indicated).

**Restaging**
When positron emission tomography (PET) results may assist in the following situations positron emission tomography (PET) scanning may be **eligible for coverage**:
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

For the purpose of detecting suspected recurrence, or to determine the extent of a biopsy-proven progressive, persistent, or recurrent disease when standard imaging was equivocal.

Investigational
When used for applications not discussed above, positron emission tomography (PET) scanning for the evaluation of Merkel cell carcinoma is considered investigational*.

Multiple Myeloma
Eligible for Coverage

Staging Positron emission tomography (PET) scanning in the staging of multiple myeloma to assess extent of disease at time of diagnosis, when the skeletal survey and/or whole body MRI is negative for bone involvement, i.e., for differentiation of smoldering myeloma from active myeloma, may be eligible for coverage.**

Restaging Positron emission tomography (PET) scanning in the restaging of multiple myeloma after completion of treatment when routine evaluation with laboratory findings or bone survey suggests recurrence or progression of disease, may be eligible for coverage.**

Note: Routine evaluation includes quantitative immunoglobulins and M protein (serum and urine), CBC, kidney function, calcium levels, and bone survey. Additional evaluation may also include bone marrow aspirate and biopsy, serum free light chain assay, MRI, and flow cytometry.

Neuroendocrine Tumors
Eligible for Coverage

Diagnosis Positron emission tomography (PET) scanning with gallium 68 as a technique for suspected well-differentiated neuroendocrine tumors based on endoscopy, conventional imaging, or biochemical markers, when not amenable to biopsy, may be eligible for coverage.**

Staging Positron emission tomography (PET) scanning with gallium 68 as a technique for initial staging of biopsy-proven well-differentiated neuroendocrine tumors may be eligible for coverage.**

Restaging Positron emission tomography (PET) scanning with gallium 68 as a technique for restaging or for subsequent treatment strategy of well-differentiated neuroendocrine tumors may be eligible for coverage** when any of the criteria are met:

- Prior to planned peptide receptor radioligand therapy (PRRT) for well-differentiated neuroendocrine tumor; OR
- When identification of more extensive disease will change management and one of the following criteria is met:
  - Equivocal findings of disease progression on conventional imaging; OR

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

- Clinical or biochemical progression (see notes) with negative conventional imaging; OR
- When the original disease was only detectable by gallium 68 dotatate.

Notes:
Conventional imaging includes MRI or contrast-enhanced CT with or without octreotide scintigraphy. Biochemical evidence for suspected neuroendocrine cancers may include elevated levels of chromogranin A, pancreatic polypeptide, neuron-specific enolase, vasoactive intestinal polypeptide, serotonin (urinary 5-HIAA), gastrin, somatostatin, catecholamines, metanephrines, calcitonin, fasting insulin, C-peptide (proinsulin), or glucagon.

Investigational
Positron emission tomography (PET) scanning for all other indications and with other radiotracers in all aspects of managing neuroendocrine tumors is considered to be investigational.*

Ovarian Cancer
Eligible for Coverage
Restaging Positron emission tomography (PET) scanning for the evaluation of patients with signs and/or symptoms of suspected ovarian cancer recurrence (such as rising tumor markers or increasing ascites) when standard imaging, including CT scan or MRI, is inconclusive may be eligible for coverage**:

Investigational
Positron emission tomography (PET) scanning in the initial evaluation of known or suspected ovarian cancer in all situations is considered to be investigational.*

Pancreatic Cancer
Eligible for Coverage
Diagnosis When used as a technique in the initial diagnosis of pancreatic cancer when other imaging and biopsy are inconclusive positron emission tomography (PET) scanning may be eligible for coverage.**

Staging When used as a technique for staging of pancreatic cancer when other imaging and biopsy are inconclusive positron emission tomography (PET) scanning may be eligible for coverage.**

Investigational
When used as a technique to evaluate other aspects of pancreatic cancer positron emission tomography (PET) scanning is considered investigational.*
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Paraneoplastic Syndrome
Eligible for Coverage
Diagnosis When used as a technique in the initial diagnosis of occult malignancy associated with paraneoplastic syndrome when other imaging (e.g., CT neck, chest, abdomen and pelvis, MRI of brain) is inconclusive, positron emission tomography (PET) scanning may be eligible for coverage.**

Investigational
When used as a technique to evaluate other aspects of Paraneoplastic syndrome positron emission tomography (PET) scanning is considered investigational.*

Penile, Vaginal, and Vulvar Cancers
Eligible for Coverage
Staging Positron emission tomography (PET) scanning may be eligible for coverage** in EITHER of the following scenarios:
  o When standard imaging studies (e.g., CT chest, abdomen, and pelvis, or for vaginal or vulvar cancer MRI of pelvis) are equivocal or non-diagnostic for metastatic disease; OR
  o For staging of penile cancer when pelvic lymph nodes are enlarged on CT or MRI and needle biopsy is not technically feasible.

Restaging Positron emission tomography (PET) scanning may be eligible for coverage** in EITHER of the following scenarios:
  o When standard imaging studies (e.g., CT chest, abdomen, and pelvis, or for vaginal or vulvar cancer MRI of pelvis) are equivocal or non-diagnostic for metastatic disease; OR
  o For restaging of local recurrence when pelvic exenteration surgery is planned.

Investigational
When used as a technique to evaluate other aspects of penile, vaginal, and vulvar cancers positron emission tomography (PET) scanning is considered investigational.*

Cancers of the Pleura, Thymus, Heart, and Mediastinum
Eligible for Coverage
Staging Positron emission tomography (PET) scanning may be eligible for coverage** when surgical resection is being considered and metastatic disease has not been detected by CT or MRI
Positron emission tomography (PET) scanning may be eligible for coverage** for radiation treatment planning of biopsy-proven pleural malignancies, cancers of the thymus, heart, and mediastinum.

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Restaging  Positron emission tomography (PET) scanning may be **eligible for coverage** for restaging after induction chemotherapy, if patient is a surgical candidate.

Investigational
When used as a technique to evaluate other aspects of cancers of the pleura, thymus, heart, and mediastinum positron emission tomography (PET) scanning is considered **investigational.**

Note: These criteria are applicable to biopsy-proven pleural malignancies, thymoma, thymic carcinoma, and cancers of heart or mediastinum (e.g. malignant pleural mesothelioma).

Prostate Cancer

Eligible for Coverage

Restaging
Positron emission tomography (PET) scanning with $^{11}$C-choline and $^{18}$F-fluciclovine may be **eligible for coverage** when all of the following criteria are met:

- For evaluating biochemically recurrent/persistent prostate cancer after primary treatment (see note below); AND
- Results of conventional imaging are negative for metastasis or conventional imaging is not indicated (e.g. low-risk disease with T1-T3, PSA < 10 mg/mL, Gleason 6); AND
- To detect small volume disease in soft tissue when MRI of the pelvis is negative or non-diagnostic for local recurrence; AND
- Patient is a candidate for local salvage therapy, i.e. external beam radiation therapy (EBRT) with or without androgen deprivation therapy after prostatectomy, OR radical prostatectomy, cryosurgery, or brachytherapy after EBRT; AND
- PSA level is > 1 ng/mL.

Notes:
For patients who have undergone radical prostatectomy, the most widely accepted criterion for biochemical recurrence is that of the American Urological Association (AUA): a biochemical recurrence is defined as a serum PSA $\geq 0.2$ ng/mL, which is confirmed by a second determination with a PSA $\geq 0.2$ ng/mL.

For patients who have undergone EBRT or brachytherapy, the most widely accepted criterion for biochemical recurrence is that of the Radiation Therapy Oncology Group- American Society of Therapeutic Radiology and Oncology (RTOG-ASTRO) Phoenix Consensus: a biochemical recurrence is defined as a serum PSA rise of 2 ng/mL or more above the nadir PSA. Repeat confirmation is generally carried out to rule out a PSA bounce.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Investigational
When used with $^{68}$Gallium in all aspects of managing prostate cancer positron emission tomography (PET) scanning is considered investigational*.

When used for all other indications in known or suspected prostate cancer positron emission tomography (PET) scanning is considered investigational*.

Testicular Cancer
Eligible for Coverage

Restaging
When used as a technique in evaluation of residual mass following chemotherapy of stage IIB and III seminomas positron emission tomography (PET) scanning may be eligible for coverage.**

Note: The positron emission tomography (PET) scan should be completed not sooner than 6 weeks following chemotherapy.

Investigational
Except as noted above for seminoma, positron emission tomography (PET) scanning is investigational* in evaluation of testicular cancer, including but not limited to the following applications:
- Initial staging of testicular cancer;
- Distinguishing between viable tumor and necrosis/fibrosis after treatment of testicular cancer;
- Detection of recurrent disease after treatment of testicular cancer.

Thyroid Cancer
Eligible for Coverage

Initial Staging
When used in the initial staging positron emission tomography (PET) scanning may be eligible for coverage** for the following thyroid cancer subtypes: poorly differentiated papillary, anaplastic, medullary, and Hurthle cell cancer.

Restaging
Positron emission tomography (PET) scanning may be eligible for coverage** in EITHER of the following scenarios:
- For follow up of poorly differentiated papillary, anaplastic, medullary, or Hurthle cell carcinoma: OR
- For evaluation of suspected recurrence of well-differentiated papillary or follicular thyroid cancer when I-131 scan is negative (or has been negative in past) and stimulated thyroglobulin level is > 2 ng/dL in the absence of antibodies.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Note: PET is most useful for non-iodine-avid thyroid cancer. Alternative imaging modalities should be considered in those tumor types for which falsely negative PET or PET/CT results are commonly reported, including medullary thyroid carcinoma.

Investigational
When used as a technique in the evaluation of known or suspected thyroid cancer in all other situations positron emission tomography (PET) scanning is considered investigational.*

Unknown Primary
Eligible for Coverage
Diagnosis
When used in patients with an unknown primary who meet ALL of the following criteria positron emission tomography (PET) scanning may be eligible for coverage**:
  o Single site of disease outside the cervical lymph nodes; and
  o Patient is considering local or regional treatment for a single site of metastatic disease; and
  o Negative workup for an occult primary tumor; and
  o Positron emission tomography (PET) scan will be used to rule out or detect additional sites of disease that would eliminate the rationale for local or regional treatment.

Investigational
Diagnosis
Positron emission tomography (PET) scanning is considered investigational* in evaluation of unknown primary, including but not limited to the following applications:
  o As part of the initial workup of an unknown primary;
  o As part of the workup of patients with multiple sites of disease.

Cancer Surveillance
Positron emission tomography (PET) scanning is considered investigational* when used as a surveillance tool for patients with cancer or with a history of cancer. A scan is considered surveillance if performed more than 6 months after completion of cancer therapy (12 months for lymphoma) in patients without objective signs or symptoms suggestive of cancer recurrence.

Policy Guidelines
PATIENT SELECTION
As with any imaging technique, the medical necessity of positron emission tomography (PET) scanning depends in part on what imaging techniques are used before or after the PET scanning. Due to its expense, PET scanning is typically considered after other techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), or ultrasonography, provide inconclusive or discordant results. In patients with melanoma or lymphoma, PET scanning may be considered an initial imaging technique. If so, the medical

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
necessity of subsequent imaging during the same diagnostic evaluation is unclear. Thus, PET should be considered for the medically necessary indications above only when standard imaging (eg, CT, MRI) is inconclusive or not indicated.

Patient selection criteria for PET scanning also may be complex. For example, it may be difficult to determine from claims data whether a PET scan in a patient with malignant melanoma is being done primarily to evaluate extranodal disease or regional lymph nodes. Similarly, it may be difficult to determine whether a PET scan in a patient with colorectal cancer is being performed to detect hepatic disease or evaluate local recurrence. Due to the complicated hierarchy of imaging options in patients with malignancy and complex patient selection criteria, a possible implementation strategy for this policy is its use for retrospective review, possibly focusing on cases with multiple imaging tests, including PET scans.

Use of PET scanning for surveillance as described in the policy statement and policy rationale refers to the use of PET to detect disease in asymptomatic patients at various intervals. This is not the same as the use of PET for detecting recurrent disease in symptomatic patients; these applications of PET are considered within tumor-specific categories in the policy statements.

Background/Overview
A variety of tracers are used for positron emission tomography (PET) scanning, including oxygen 15, nitrogen 13, carbon 11 choline, and fluorine 18. In 2016, 2 additional tracers, gallium 68 and fluciclovine 18, were approved by the Food and Drug Administration. Because of their short half-life, some tracers must be made locally using an onsite cyclotron. The radiotracer most commonly used in oncology imaging has been fluorine 18 coupled with fluorodeoxyglucose (FDG), which correlates with glucose metabolism. FDG has been considered useful in cancer imaging because tumor cells show increased metabolism of glucose. The most common malignancies studied have been melanoma, lymphoma, lung, colorectal, and pancreatic cancer.

For this evidence review, PET scanning is discussed for the following 4 applications in oncology: diagnosis, staging, restaging, and surveillance. Diagnosis refers to use of PET as part of the testing used in establishing whether a patient has cancer. Staging refers to the use of PET to determine the stage (extent) of cancer at the time of diagnosis before any treatment is given. Imaging at this time is generally to determine whether the cancer is localized. This also may be referred to as initial staging. Restaging refers to imaging after treatment in 2 situations. Restaging is part of the evaluation of a patient in whom disease recurrence is suspected based on signs and/or symptoms. Restaging also includes determining the extent of malignancy after completion of a full course of treatment. Surveillance refers to the use of imaging in asymptomatic patients (patients without objective signs or symptoms of recurrent disease). This imaging is completed 6 months or more (≥12 months for lymphoma) after completion of treatment.

This evidence review focuses on the use of radiotracers detected with dedicated PET scanners. Radiotracers such as FDG may be detected using single-photon emission computerized tomography cameras, a technique that may be referred to as FDG-single-photon emission computerized tomography imaging. The use of single-
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Photon emission computerized tomography cameras for PET radiotracers presents unique issues of diagnostic performance and is not considered herein.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**
The Food and Drug Administration website includes various PET-related documents.

As of July 2018, the following radiopharmaceuticals have been granted approval by the Food and Drug Administration, to be used with PET for carcinoma-related indications (see Table 1).

### Table 1. Radiopharmaceuticals Approved for Use With PET for Oncologic Applications

<table>
<thead>
<tr>
<th>Radiopharmaceutical</th>
<th>Manufacturer</th>
<th>Name</th>
<th>Carcinoma-Related Indication With PET</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbon-11 choline (C-11)</td>
<td>Various</td>
<td></td>
<td>Suspected prostate cancer recurrence based on elevated blood PSA after therapy and noninformative bone scintigraphy, CT, or MRI</td>
</tr>
<tr>
<td>Fluorine-18 fluorodeoxyglucose (FDG)</td>
<td>Various</td>
<td></td>
<td>Suspected or existing diagnosis of cancer, all types</td>
</tr>
<tr>
<td>Fluorine-18 fluciclovine</td>
<td>Blue Earth Diagnostics</td>
<td>Axumin™</td>
<td>Suspected prostate cancer recurrence based on elevated blood PSA levels after treatment</td>
</tr>
<tr>
<td>Gallium-68 dotatate</td>
<td>Advanced Accelerator Applications</td>
<td>NETSPOT™</td>
<td>Localization of somatostatin receptor positive NETs in adult and pediatric patients</td>
</tr>
</tbody>
</table>

CT: computerized tomography; MRI: magnetic resonance imaging; NET: neuroendocrine tumors; PET: positron emission tomography; PSA: prostate-specific antigen.

**Centers for Medicare and Medicaid Services (CMS)**
The Medicare coverage policy on positron emission tomography scans was updated in 2009 and last reviewed in August 2010.

**Rationale/Source**

**ANAL CANCER**

Anal cancer, which arises from the cells of the anal canal or anal margin, accounts for 3% of all gastrointestinal cancers. The most common histological subtype is squamous cell carcinoma. Risk factors for developing anal cancer include high-risk sexual behavior, tobacco use, and infection with human papillomavirus or human immunodeficiency virus. The most common presentation is rectal bleeding or pain.

**INITIAL TREATMENT STRATEGY**

Anal cancer is staged using the American Joint Committee on Cancer TNM system. The vast majority of patients with locoregional disease will undergo concurrent chemoradiation treatment regardless of tumor or nodal staging.

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
PET/CT scan in initial staging and radiation planning allows for better assessment of nodal metastases which may alter the radiation plan for curative combined modality therapy. A meta-analysis of 12 studies found that CT and PET had a sensitivity of 60% and 99%, respectively, for the detection of primary disease. Compared with conventional imaging, PET upstaged 15% and downstaged another 15% of nodal disease. This led to a change in nodal staging in 28% and TNM staging in 41% of patients. A more recent meta-analysis published by Mahmud et al. found a pooled sensitivity of 99% for PET or PET/CT and 67% for CT scan alone. PET imaging also had a sensitivity of 93% and specificity of 76% for detecting nodal disease. A total of 5.1% to 37.5% of patients were upstaged and 8.2% to 26.7% were downstaged with 12.5% to 59.3% of patients requiring treatment changes. However, the majority of the changes in treatment were in radiation planning.

SUBSEQUENT TREATMENT STRATEGY
Following completion of concurrent chemoradiation therapy, the National Comprehensive Cancer Network (NCCN) recommends that initial follow up of anal cancer include digital rectal exam 8 to 12 weeks after treatment. Patients with persistent disease but without evidence of progression may be managed with close followup for up to 6 months. In the event of biopsy-proven progressive disease or recurrence, reimaging can be performed with conventional advanced imaging or PET/CT scan when salvage surgery is indicated. The 5-year overall survival was 64% in a small study of 39 patients treated with radical salvage surgery.

BLADDER CANCER

Systematic Reviews
A systematic review and meta-analysis (10 studies, total N=433 patients) by Zhang et al (2015) evaluated the diagnostic accuracy of FDG-PET and FDG-PET with CT (FDG-PET/CT) in patients with urinary bladder cancer. The 10 studies were assessed for quality using the 14-item Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool. Median QUADAS score was 9 (range, 7-10). Nine of the 10 studies used FDG-PET/CT and 1 used FDG-PET. Nine studies were retrospective and 1 prospective. Meta-analyses showed relatively high sensitivity (82%; 95% confidence interval [CI], 75% to 88%) and specificity (92%; 95% CI, 87% to 95%) in the diagnosis of bladder cancer, with the reference test of pathology results. The meta-analysis funnel plots showed some asymmetry, indicating a potential for publication bias.

Guidelines

American College of Radiology
The American College of Radiology (ACR; 2018) issued an Appropriateness Criteria for pretreatment staging of muscle-invasive bladder cancer. ACR stated that FDG-PET/CT "may be appropriate" for the pretreatment staging of muscle-invasive bladder cancer. However, the ACR cited CT, MRI, and chest radiographs as the most appropriate imaging techniques for pretreatment staging.

National Comprehensive Cancer Network
Current National Comprehensive Cancer Network (NCCN) guidelines for bladder cancer (v.5.2018) state that PET/CT "may be beneficial in selected patients with T2 (muscle-invasive disease) and in patients with ≥cT3
Positron Emission Tomography (PET) Oncology Applications

Policy #     00105
Original Effective Date:   01/28/2002
Current Effective Date:  06/01/2019

disease” (category 2B).” According to the guidelines, PET/CT may also be considered if metastasis is suspected in high-risk patients (category 2B). However, the guidelines note that “PET/CT should not be used to delineate the anatomy of the upper urinary tract” or in patients with nonmuscle invasive bladder cancer.

Section Summary: Bladder Cancer
Evidence for the use of FDG-PET and FDG-PET/CT for the diagnosis and for the staging and restaging of muscle-invasive bladder cancer consists of a systematic review and meta-analysis of several studies. Pooled analyses have shown that PET/CT is effective in the staging of muscle-invasive bladder cancer. The evidence supports the use of PET/CT for the diagnosis and staging and restaging of muscle-invasive bladder cancer.

The evidence does not support the use of FDG-PET/CT for nonmuscle invasive bladder cancer.

BONE AND SOFT TISSUE SARCOMA
Sarcomas account for fewer than 1% of all adult malignancies. Sarcomas are a heterogeneous group of cancers which arise from mesenchymal cells and occur in many different types of tissue, most commonly bone, muscle, and cartilage. Risk factors are not well characterized but may include genetic predisposition, prior chemotherapy or radiation therapy, and environmental exposure.

INITIAL TREATMENT STRATEGY
Sarcomas are staged using the American Joint Committee on Cancer TNM system. Imaging of the primary tumor is important to assess resectability and local invasion. MRI is preferred for imaging of the primary tumor due to superior resolution of tumor versus surrounding muscle and neurovascular bundles. In a large prospective trial comparing CT and MRI imaging in both soft tissue sarcomas and bone cancer, the accuracy of local staging of primary malignant bone and soft tissue tumors was not statistically different between the 2 modalities. Since CT is less susceptible to motion artifact, CT is preferable to MRI for patients with retroperitoneal and intra-abdominal soft tissue sarcomas. Anatomic relationship of the tumor to other abdominal organs is well visualized by CT, as is metastatic disease in the liver or peritoneum.

Imaging of the lungs is critical, as this is the most common site of metastases. Additional imaging recommendations for soft tissue sarcoma vary by subtype. Multiple studies have shown a correlation between FDG uptake and tumor grade, which is a strong indicator of prognosis. However, the evidence has not shown that PET significantly impacts staging or management.

For Ewing sarcoma, MRI of the spine and pelvis is indicated for detection of skeletal metastases. A meta-analysis showed a pooled sensitivity of 96% and pooled specificity of 92% with resultant change in management for staging and restaging when PET was combined with conventional imaging. PET response correlates with histopathologic response, improvement in progression-free survival, and potential change in management. In another meta-analysis of 42 trials, PET had a pooled sensitivity and specificity of 96% and 79% for differentiating primary bone sarcomas from benign lesions, 92% and 93% for detecting recurrence, and 90% and 85% for detecting distant metastasis, respectively.

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
SUBSEQUENT TREATMENT STRATEGY
PET has been shown to be a useful adjunct in assessing treatment response to neoadjuvant therapy, as well as an indicator of prognosis. A review and meta-analysis of 11 studies confirmed the prognostic value of PET response to overall survival in soft tissue and bone sarcoma.

SURVEILLANCE
Imaging of the primary site for soft tissue sarcoma is based on the risk of recurrence and the accessibility of the primary cancer site. Ultrasound is an underutilized tool for surveillance of soft tissue sarcoma; one study found no discernable difference in detection of local recurrences when comparing ultrasound with MRI.

BRAIN AND SPINAL CORD MALIGNANCY
Primary brain and spinal cord tumors encompass a large and heterogeneous group of cancers that range from benign to highly aggressive. Glioblastomas are the most common high-grade primary central nervous system cancer, and comprise about 15% of primary brain cancers. Risk factors for brain and spinal cord cancers include genetic predisposition and radiation exposure. The most common presentation is focal neurological symptoms based on the region of brain involved.

INITIAL TREATMENT STRATEGY
The World Health Organization Classification of Tumors of the Central Nervous System is used to classify and grade gliomas. All patients require an MRI of the brain for initial evaluation unless contraindicated. Spine imaging is indicated for intracranial and spinal ependymoma, medulloblastoma, primary spinal cord tumors, leptomeningeal disease, and symptomatic or cerebrospinal fluid-positive central nervous system lymphoma. Systemic imaging is also indicated for central nervous system lymphomas; one study found that PET/CT had a significantly higher sensitivity (94%-98%) than CT imaging and resulted in change in management in 34% of patients. However, the evidence to date is limited and PET imaging is currently a National Comprehensive Cancer Network (NCCN) level 2B recommendation.

SUBSEQUENT TREATMENT STRATEGY
MR perfusion/angiography, fMRI, MRS, or PET scan may be used to differentiate radiation necrosis from active tumor. Limited data have confirmed the utility of MR perfusion in identifying tumor response in high-grade gliomas. In a study comparing MRI to MRS, MRS plus diffusion-weighted imaging sequences was found to have above 95% sensitivity and specificity for distinguishing bacterial abscess from cystic tumor. In a meta-analysis comparing the accuracy of MRS to PET, there was no significant difference between the two modalities.
BREAST CANCER

Breast Cancer Diagnosis

Systematic Reviews
Liang et al (2017) also conducted a meta-analysis on the use of PET/CT to assess axillary lymph node metastasis. Results from the meta-analyses of 14 studies using MRI and 10 studies using PET/CT showed that MRI had a higher sensitivity in diagnosing axillary lymph node status.

In a meta-analysis of 8 studies (total N=873 patients) on FDG-PET performed in women with newly discovered suspicious breast lesions, Caldarella et al (2014) reported pooled sensitivity and specificity of 85% (95% CI, 83% to 88%) and 79% (95% CI, 74% to 83%), respectively, on a per-lesion basis. As previously noted, a false-negative rate of 15% (1 – sensitivity) may be considered unacceptable given the relative ease of breast biopsy.

A systematic review by Sloka et al (2007) on PET for staging axillary lymph nodes identified 20 studies. Three of these 20 studies were rated high quality, indicating broad generalizability to a variety of patients and no significant flaws in research methods. The remaining studies were less generalizable due to flaws in the methodology. Reviewers observed that there was great variability in estimates of sensitivity and specificity from the selected studies and that it was difficult to draw conclusions from the evidence.

A TEC Assessment (2001) focused on multiple applications of PET scanning in breast cancer, including characterizing breast lesions, staging axillary lymph nodes, detecting recurrence, and evaluating response to treatment. A TEC Assessment (2003) reexamined all indications except for characterizing breast lesions. The bulk of the data on FDG-PET for breast cancer focuses on its ability to characterize breast lesions further such that patients could avoid biopsy of a mammographically indeterminate or suspicious lesion. The key statistic in this analysis is the false-negative rate, because patients with a false-negative result on a PET scan may inappropriately forgo a biopsy and subsequent treatment. The false-negative rate will vary with the underlying prevalence of the disease but may range from 5.5% to 8.5%. Given the relative ease of breast biopsy, this false-negative rate may be considered unacceptable, and thus patients may undergo biopsy regardless of the results of a PET scan.

Breast Cancer Staging
A meta-analysis by Hong et al (2013) reported a sensitivity and a specificity of FDG-PET/CT in diagnosing distant metastases in breast cancer patients of 96% (95% CI, 90% to 98%) and 95% (95% CI, 92% to 97%), respectively, based on 8 studies (n=748). In a meta-analysis of 6 comparative studies (n=664 patients), the sensitivity and specificity were 97% (95% CI, 84% to 99%) and 95% (95% CI, 93% to 97%) compared with 56% (95% CI, 38% to 74%) and 91% (95% CI, 78% to 97%) with conventional imaging, all respectively.

Rong et al (2013) conducted a meta-analysis of 7 studies (total N=668 patients) and reported that the sensitivity and specificity of FDG-PET/CT were greater than bone scintigraphy for detecting bone metastasis.
in breast cancer patients. The sensitivity and specificity of FDG-PET/CT were 93% (95% CI, 82% to 98%) and 99% (95% CI, 95% to 100%) compared with 81% (95% CI, 58% to 93%) and 96% (95% CI, 76% to 100%) for bone scintigraphy, all respectively.

A meta-analysis by Isasi et al (2005) focused on PET for detecting recurrence and metastases. The analysis concluded that PET is a valuable tool; however, they did not compare PET performance with that of other diagnostic modalities, so it is unclear whether the use of PET resulted in different management decisions and health outcomes.

The TEC Assessment (2003) described above in the Breast Cancer Diagnosis section concluded that the use of FDG-PET for staging axillary lymph nodes did not meet TEC criteria.

**Breast Cancer Restaging**

A systematic review by Xiao et al (2016) evaluated the diagnostic efficacy of FDG-PET and FDG-PET/CT in detecting breast cancer recurrence. The literature search, conducted through January 2016, identified 26 studies (total N=1752 patients) for inclusion in the analysis; 12 studies used PET and 14 studies used PET/CT. Fourteen studies had QUADAS scores greater than 10. Reasons for suspected recurrence in the 1752 patients were: elevated tumor markers (57%), suspicion from conventional imaging modalities (34%), and suggestive clinical symptoms or physical examination results (9%). Pooled sensitivity and specificity are presented in Table 2. Subgroup analyses showed that PET/CT was more specific than PET alone in diagnosing recurrent breast cancer (p=0.035).

A systematic review by Liu et al (2016) compared FDG-PET or FDG-PET/CT with MRI in assessing pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. The literature search, conducted through August 2015, identified 6 studies (total N=382 patients) for inclusion. Quality assessment of the studies was satisfactory using the QUADAS-2 scale. Meta-analysis results are presented in Table 2.

In another meta-analysis comparing FDG-PET with MRI and evaluating pathologic complete response to neoadjuvant chemotherapy (NAC) in patients with breast cancer, Sheikhbahaei et al (2016) selected 10 studies for analysis. The inclusion criteria differed slightly from Liu (2016). Liu et al required that both FDG-PET and MRI be performed before and during (or after) NAC, while Sheikhbahaei et al (2016) did not require the scanning before NAC. Pooled sensitivities and specificities are listed in Table 2. Subgroup analysis was performed, by the time of scanning (during NAC and after NAC was completed).

Other reviews, including Li et al (2018), have also compared MRI with PET or PET/CT in evaluating response to NAC. Meta-analytic results are similar to previous studies and are presented in Table 2.
Table 2. Pooled Diagnostic Performance of FDG-PET and MRI in Detection of Residual Disease After NAC for Breast Cancer

<table>
<thead>
<tr>
<th>Type of Imaging</th>
<th>No. of Studies (Patients)</th>
<th>Sensitivity (95% CI), %</th>
<th>Specificity (95% CI), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li et al (2018)</td>
<td>MRI</td>
<td>13 (575)</td>
<td>88 (78 to 94)</td>
</tr>
<tr>
<td></td>
<td>FDG-PET or FDG-PET/CT</td>
<td>13 (618)</td>
<td>77 (58 to 90)</td>
</tr>
<tr>
<td>Xiao et al (2016)</td>
<td>FDG-PET or FDG-PET/CT</td>
<td>26 (1752)</td>
<td>90 (88 to 90)</td>
</tr>
<tr>
<td>Liu et al (2016)</td>
<td>MRI</td>
<td>6 (382)</td>
<td>65 (45 to 80)</td>
</tr>
<tr>
<td></td>
<td>FDG-PET or FDG-PET/CT</td>
<td>6 (382)</td>
<td>86 (76 to 93)</td>
</tr>
<tr>
<td>Sheikhbahaei et al (2016)</td>
<td>All studies</td>
<td>MRI 10 (492)</td>
<td>88 (76 to 95)</td>
</tr>
<tr>
<td></td>
<td>FDG-PET or FDG-PET/CT</td>
<td>10 (535)</td>
<td>71 (52 to 85)</td>
</tr>
<tr>
<td></td>
<td>FDG-PET/CT</td>
<td>7 (385)</td>
<td>82 (62 to 92)</td>
</tr>
<tr>
<td></td>
<td>FDG-PET</td>
<td>3 (150)</td>
<td>43 (26 to 63)</td>
</tr>
<tr>
<td>During NAC</td>
<td>MRI</td>
<td>3 (256)</td>
<td>89 (66 to 97)</td>
</tr>
<tr>
<td></td>
<td>FDG-PET/CT</td>
<td>3 (256)</td>
<td>91 (86 to 95)</td>
</tr>
<tr>
<td>After NAC completion</td>
<td>MRI</td>
<td>7 (236)</td>
<td>88 (71 to 96)</td>
</tr>
<tr>
<td></td>
<td>FDG-PET or FDG-PET/CT</td>
<td>7 (279)</td>
<td>57 (40 to 71)</td>
</tr>
<tr>
<td></td>
<td>FDG-PET/CT</td>
<td>4 (129)</td>
<td>71 (42 to 89)</td>
</tr>
</tbody>
</table>

CI: confidence interval; CT: computed tomography; FDG: fluorine 18 fluorodeoxyglucose; MRI: magnetic resonance imaging; NAC: neoadjuvant chemotherapy; PET: positron emission tomography.

Two 2012 meta-analyses pooled studies on the use of FDG-PET to predict pathologic response to neoadjuvant therapy before surgery for locally advanced breast cancer. Both reviews reported similar pooled point estimates for sensitivity and specificity. Both concluded that PET had reasonably high sensitivity and relatively low specificity. Neither described how PET should be used to influence patient management decisions and therefore whether health outcomes would be changed relative to decisions not based on PET results. Thus, it is unclear whether PET improves outcomes for predicting pathologic response to neoadjuvant therapy for locally advanced breast cancer.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

An NCCN review conducted by Podoloff et al (2007) concluded that PET was optional and might be useful for staging and restaging regional or distant metastasis when suspicion is high and other imaging is inconclusive.

Guidelines

American College of Radiology
ACR issued an Appropriateness Criteria for the initial workup and surveillance for local recurrence and distant metastases in asymptomatic women with stage I breast cancer. ACR noted that FDG-PET/CT is usually not appropriate during initial workup or surveillance of these patients, to rule out metastases.

National Comprehensive Cancer Network
Current NCCN guidelines on breast cancer (v.1.2018) include an optional category 2B recommendation for FDG-PET/CT in the workup of stage IIIA breast cancer.

NCCN recommends against FDG-PET/CT for lower stage breast cancer (I, II, or operable III) due to high false-negative rates in detecting low-grade lesions or lesions less than 1 cm; low sensitivity in detecting axillary node metastasis; the low prior probability of detectable metastases in these patients; and high false-positive rates. NCCN considers PET or PET/CT most helpful when “standard staging studies are equivocal or suspicious, especially in the setting of locally advanced or metastatic disease.”

NCCN guidelines do not recommend routine use of PET in asymptomatic patients for surveillance and follow-up after breast cancer treatment. When monitoring metastatic disease, the guidelines note that PET is “challenging because of the absence of a reproducible, validated, and widely accepted set of standards for disease activity assessment.”

Section Summary: Breast Cancer
Evidence for the use of PET or PET/CT in patients with breast cancer consists of TEC Assessments, systematic reviews, and meta-analyses. There is no evidence that PET is useful in diagnosing breast cancer. The false-negative rates of PET in patients with breast cancer are estimated to be between 5.5% and 8.5%, which can be considered unacceptable, given that breast biopsy can provide more definitive results. PET/CT might be useful in detecting metastases when results from other imaging techniques are inconclusive. The evidence supports the use of FDG-PET and FDG-PET/CT for staging and restaging only if standard staging methods are inconclusive.

The evidence does not support the use of FDG-PET and FDG-PET/CT for diagnosis, staging, and restaging when standard staging methods are conclusive.

The evidence does not support the use of FDG-PET or FDG-PET/CT for surveillance of breast cancer.

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
CERVICAL CANCER

Systematic Reviews
In a systematic review of 20 studies, Chu et al (2014) reported a pooled sensitivity and specificity for FDG-PET or FDG-PET/CT of 87% (95% CI, 80% to 92%) and 97% (95% CI, 96% to 98%), respectively, for distant metastasis in recurrent cervical cancer. For local regional recurrence, pooled sensitivity and specificity were 82% (95% CI, 72% to 90%) and 98% (95% CI, 96% to 99%), respectively.

In a meta-analysis of 9 cervical cancer recurrence studies, Rong et al (2013) reported a sensitivity and a specificity for PET/CT of 94.8% (95% CI, 91.2% to 96.9%) and 86.9% (95% CI, 82.2% to 90.5%), respectively. Reviewers found the quality of studies on recurrence was average with some limitations. For example, studies included mostly symptomatic women and did not differentiate between PET for diagnosis or surveillance.

An Agency for Healthcare Research and Quality (AHRQ) review (2008) identified several studies using FDG-PET or FDG-PET/CT to stage advanced cervical cancer and to detect and stage recurrent disease. The report concluded that most studies supported enhanced diagnostic accuracy, which would improve the selection of appropriate treatment for patients. For recurrent disease, PET identified additional sites of metastasis, which would alter treatment decisions in some cases. For example, in a study by Yen et al (2004) of 55 patients whose recurrences were initially considered curable with radical surgical treatment, 27 instead underwent palliative therapy based on PET results. An NCCN report conducted by conducted by Podoloff et al (2009) also identified several studies supporting the use of PET for initial staging and identifying and staging recurrent disease.

Guidelines
Current NCCN guidelines on cervical cancer (v2.2018) state that PET/CT may be considered under the following conditions:

- Part of the initial nonfertility and fertility-sparing workup for patients with stage I cervical cancer.
- Part of the initial staging workup for detection of stage II, III, or IV metastatic disease
- Follow-up/surveillance for stage I (only nonfertility sparing) through stage IV at 3 to 6 months after completion of therapy or if there is suspected recurrence or metastases.

Section Summary: Cervical Cancer
Evidence for the use of PET in patients with cervical cancer consists of systematic reviews and meta-analyses. Pooled results have shown that PET can be used for staging or restaging and detecting recurrent disease. The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis and staging and restaging of cervical cancer.

The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of cervical cancer.
COLORECTAL CANCER

CRC Diagnosis

Systematic Reviews
Mahmud et al (2017) conducted a systematic review comparing the use of FDG-PET and -FDG-PET/CT with conventional imaging techniques in the staging, treatment response, and follow-up of patients with rectal cancer. The literature review, conducted through April 2016, identified 17 studies (total N=791 patients) for the qualitative review, with 8 of those studies (n=428 patients) included in the meta-analyses. The QUADAS-2 tool was used to assess study quality. A limitation of many of the studies was that there was either no blinding or unclear blinding of the assessors of the index test or the reference standard. For the detection of a primary tumor, pooled sensitivity and specificity were 99% (95% CI, 97% to 100%) and 67% (95% CI, 50% to 82%), respectively. For the detection of inguinal lymph nodes, the pooled sensitivity and specificity were 93% (95% CI, 76% to 99%) and 76% (95% CI, 61% to 87%), respectively.

A systematic review by Jones et al (2015) compared the role of -FDG-PET and FDG-PET/CT with conventional imaging in the detection of primary nodal disease. Twelve studies met inclusion criteria (total N=494 patients). Meta-analysis for detecting primary disease in situ showed that PET and PET/CT had a higher sensitivity (99%; 95% CI, 96% to 100%) than CT alone (60%; 95% CI, 46% to 75%).

Two clinical applications of PET scanning were considered in a TEC Assessment (1999): (1) to detect hepatic or extrahepatic metastases and to assess their resectability in patients with colorectal cancer (CRC), either as part of initial staging or after primary resection, and (2) to evaluate the presence of postoperative scar vs recurrent disease as a technique to determine the necessity of tissue biopsy.

The body of evidence indicated that PET scanning added useful information to conventional imaging in detecting hepatic and extrahepatic metastases. In particular, PET detected additional metastases leading to more identification of nonresectable disease, allowing patients to avoid surgery. The strongest evidence came from a study that directly assessed the additional value of PET. In a group of 37 patients thought to have a solitary liver metastasis by conventional imaging, PET correctly upstaged 4 patients and falsely overstaged 1 patient. This and another study found that when PET results were discordant with conventional imaging results, PET was correct in 88% and 97% of patients, respectively. When PET affected management decisions, it was more often used to recommend against surgery.

When used to distinguish between local recurrence and scar, the comparison is between performing histologic sampling in all patients with a suspected local recurrence and avoiding sampling in patients whose PET scans suggest the presence of postoperative scar. The key concern is whether the negative predictive value (NPV) for PET is sufficiently high to influence decision making, specifically to avoid tissue biopsy when the PET scan is negative. The TEC Assessment found that studies then available suggested an 8% probability of false-negative results making it unlikely that patients and physicians would forgo histologic sampling and delay potentially curative repeat resection.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

CRC Staging

Systematic Reviews
Results from a meta-analysis by Albertsson et al (2018) found that PET/CT influenced treatment plans, though the impact on survival and quality of life could not be determined.

A meta-analysis by Ye et al (2015) assessed the use of FDG-PET/CT in preoperative TNM staging of CRC. The literature search, conducted through July 2014, identified 28 studies for inclusion. Of the 28 studies, 12 assessed tumor detection rates; 4 evaluated T staging, 20 N staging, and 5 M staging; while 8 examined stage change. Using the QUADAS tool, all studies met 9 or more of the 14 criteria. Pooled diagnostic estimates are listed in Table 3.

Three systematic reviews published in 2014 included overlapping studies that assessed the predictive value of FDG-PET/CT in patients with locally advanced rectal cancer who received neoadjuvant chemoradiotherapy. Various PET parameters were investigated (standardized uptake value, response index [percentage of the standardized uptake value decrease from baseline to post neoadjuvant treatment]), and cutoff values varied. Pooled sensitivities ranged from 74% to 82%, and pooled specificities ranged from 64% to 85%. The value of FDG-PET/CT in this setting has yet to be established.

Two systematic reviews were conducted to evaluate the use of PET/CT for radiotherapy planning in patients with rectal cancer. Gwynne et al (2012) compared different imaging techniques for radiotherapy treatment planning and concluded that additional studies would be needed to validate the use of PET in this setting.

Table 3. Pooled Diagnostic Performance of FDG-PET, FDG-PET/CT, and CT Alone in the Staging of Colorectal Cancer

<table>
<thead>
<tr>
<th>Type of Imaging</th>
<th>No. of Studies</th>
<th>Diagnostic Threshold</th>
<th>Sensitivity (95% CI), %</th>
<th>Specificity (95% CI), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>T staging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDG-PET or FDG-PET/CT</td>
<td>4</td>
<td>Yes</td>
<td>73 (65 to 81)</td>
<td>99 (98 to 99)</td>
</tr>
<tr>
<td>N staging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDG-PET or FDG-PET/CT</td>
<td>20</td>
<td>Yes</td>
<td>62 (59 to 66)</td>
<td>70 (67 to 73)</td>
</tr>
<tr>
<td>FDG-PET/CT alone</td>
<td>12</td>
<td>Yes</td>
<td>70 (68 to 74)</td>
<td>63 (59 to 67)</td>
</tr>
<tr>
<td>FDG-PET alone</td>
<td>8</td>
<td>No</td>
<td>36 (29 to 44)</td>
<td>93 (89 to 96)</td>
</tr>
<tr>
<td>CT alone</td>
<td>7</td>
<td>No</td>
<td>79 (75 to 80)</td>
<td>46 (41 to 51)</td>
</tr>
<tr>
<td>M staging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDG-PET or FDG--PET/CT</td>
<td>5</td>
<td>No</td>
<td>91 (80 to 96)</td>
<td>95 (91 to 98)</td>
</tr>
<tr>
<td>CT alone</td>
<td>5</td>
<td>No</td>
<td>91 (87 to 94)</td>
<td>16 (8 to 27)</td>
</tr>
</tbody>
</table>

Adapted from Ye et al (2015).
CI: confidence interval; CT: computed tomography; FDG: fluorine 18 fluorodeoxyglucose; M staging: distant metastases; N staging: regional lymph nodes; PET: positron emission tomography; T staging: primary tumor.
CRC Restaging

Systematic Reviews
A systematic review by Rymer et al (2016) evaluated the use of FDG-PET/CT in the assessment of the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy. The literature search, conducted through April 2014, identified 10 studies (total N=538 patients) for inclusion. Selected studies were high quality, complying with an average 12.7 items on the 14-item QUADAS checklist. Tumors confirmed to have regressed following chemoradiotherapy (responders) had a higher response index mean difference of 12% (95% CI, 7% to 18%) and a lower standardized uptake value of -2.5 (95% CI, -3.0 to -1.9%) compared with nonresponders.

A meta-analysis by Yu et al (2015) evaluated the diagnostic value of FDG-PET/CT for detecting local recurrent CRC. The literature search, conducted through October 2014, identified 26 studies (total N=1794 patients) for inclusion. Study quality was assessed using QUADAS. Pooled sensitivity and specificity were 95% (95% CI, 93% to 97%) and 93% (95% CI, 92% to 95%), respectively.

Maffione et al (2015) conducted a systematic review of FDG-PET for predicting response to neoadjuvant therapy in patients with rectal cancer. The literature search was conducted through January 2014, with 29 studies meeting inclusion criteria for the meta-analysis. The studies had QUADAS scores ranging from 8 to 14 (median, 12). The pooled sensitivity and specificity for FDG-PET assessment of response to chemoradiotherapy in locally advanced rectal cancer were 73% (95% CI, 71% to 76%) and 77% (95% CI, 75% to 79%), respectively.

In a systematic review, Lu et al (2013), evaluated 510 patients from 11 studies on FDG-PET for CRC tumor recurrence detection in patients with elevated carcinoembryonic antigen. The literature search ran through April 2012. FDG-PET and PET/CT pooled sensitivity estimates were 90.3% (95% CI, 85.5% to 94.0%) and 94.1% (95% CI, 89.4% to 97.1%), respectively, and specificities were 80.0% (95% CI, 67.0% to 89.6%) and 77.2% (95% CI, 66.4% to 85.9%), respectively.

CRC Surveillance

Randomized Controlled Trials
Sobhani et al (2018) conducted an open-label RCT to determine whether adding 6 monthly FDG-PET/CT scans to usual surveillance (3 monthly physicals and tumor marker assays; 6 monthly liver ultrasounds and chest radiographs; 6 monthly CT scans) of patients with CRC following surgery and/or chemotherapy improves health outcomes. A total of 239 patients in remission were enrolled, 120 in the intervention arm and 119 in the control arm. After 3 years follow-up, the failure rate in the intervention group was 29% (31 unresectable recurrences, 4 deaths) and 24% in the control group (27 unresectable recurrences, 1 death), which was not a statistically significant difference.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Guidelines

American College of Radiology
ACR (2017) issued an Appropriateness Criteria for the pretreatment staging of CRC. In the evaluation of distant metastases, the criteria stated that "routine use of PET/CT is likely not indicated; however, it may provide guidance in cases of advanced, bilobar liver disease to exclude extrahepatic metastases prior to surgical intent to cure."

National Comprehensive Cancer Network
Current NCCN guidelines for colon cancer (v.2.2018) "strongly discourage the routine use of PET/CT scanning for staging, baseline imaging, or routine follow-up and recommend consideration of a preoperative PET/CT scan at baseline only if prior anatomic imaging indicates the presence of potentially surgically curable M1 disease." For initial workup of nonmetastatic patients, the guidelines state “PET/CT does not supplant a contrast-enhanced diagnostic CT scan. PET/CT should only be used to evaluate an equivocal finding on a contrast-enhanced CT scan or in patients with strong contraindications to IV [intravenous] contrast.” For workup of proven metastatic synchronous adenocarcinoma, the guidelines state that PET/CT may be considered. PET/CT is not recommended for surveillance. NCCN has noted that PET/CT should not be used to assess response to chemotherapy. NCCN was divided on the appropriateness of PET/CT when carcinoembryonic antigen level is rising; PET/CT might be considered when imaging study results (eg, a good quality CT scan) are normal.

Current NCCN guidelines for rectal cancer (v.2.2018) state that PET/CT is "not routinely indicated" and "should only be used to evaluate an equivocal finding on a contrast-enhanced CT scan or in patients with strong contraindications to IV contrast." PET/CT is not recommended for restaging or for surveillance. PET/CT can be considered if serial carcinoembryonic antigen elevation occurs or if there is documented metachronous metastases.

Section Summary: Colorectal Cancer
Evidence for the detection of primary nodal disease, staging, restaging, and detecting recurrence of colorectal cancer consists of a TEC Assessment and several meta-analyses published after the assessment. A meta-analysis evaluating the diagnostic accuracy of PET or PET/CT found a high sensitivity but a low specificity. Several pooled analyses evaluating staging or restaging using PET or PET/CT resulted in sensitivities and specificities ranging from 16% to 99%. The evidence for the use of PET or PET/CT did not show a benefit over the use of contrast CT in patients with CRC. The evidence does not support the use of FDG-PET and PET/CT for the diagnosis, staging, and restaging, or surveillance of CRC.

ENDOMETRIAL (UTERINE) CANCER
Uterine cancer is the most common gynecologic cancer and fourth most common cancer among women in the U.S. The most common type of uterine cancer is endometrial, which originates in the uterine lining. Risk factors include exposure to estrogen, obesity, and genetic predisposition. The most common presentation is abnormal bleeding; the cancer may also be found incidentally on exam. Over 80% of endometrial cancers
are confined to the uterus upon discovery. The initial staging of patients with suspected endometrial cancer includes local imaging with endovaginal ultrasound or MRI pelvis.

INITIAL TREATMENT STRATEGY
The staging system most widely adopted for uterine cancer is the International Federation of Gynecology and Obstetrics (FIGO) system, although the American Joint Committee on Cancer TNM system is also used. MRI pelvis is the preferred modality for assessing the extent of local disease and extension into the cervix. For fertility-sparing therapy, an MRI pelvis is indicated prior to hormonal therapy and dilatation and curettage; a review comparing MRI to transvaginal ultrasound reported better sensitivity for evaluating myometrial invasion with MRI although statistically the two exams were equivalent. When evaluation of lymph nodes is required, both CT and MRI provide similar sensitivity and specificity. In several small studies, PET has been shown to be equivalent or moderately better for detecting nodal disease when compared to MRI and CT; however, these differences rarely affect the decision for lymphadenectomy.

As the majority of endometrial cancers are confined to the uterus (75%) and lymph nodes (10%), systemic imaging is reserved for high-risk patients. In an international prospective trial, the negative predictive value for low-risk endometrial cancer was 97%. There is insufficient data to recommend PET/CT for routine assessment. Based on the National Comprehensive Cancer Network (NCCN) uterine cancer guidelines, European Society for Medical Oncology-European Society of Gynecological Oncology-European Society for Therapeutic Radiology and Oncology Consensus, and American College of Radiology guidelines, additional imaging for metastatic workup is optional.

SUBSEQUENT TREATMENT STRATEGY
For patients who have undergone fertility-sparing treatment, MRI pelvis with contrast is preferred after 6 months of failed medical therapy. If recurrence is suspected, pelvic MRI may be used for patients with an intact uterus, and CT abdomen and pelvis should be performed if clinically indicated. In a small prospective study from Korea, PET for suspected disease recurrence had a sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 100%, 83.3%, 96%, 95%, and 100%, respectively. PET/CT detected 3/24 (12.5%) recurrences in patients with elevated tumor markers but negative CT abdomen and pelvis findings.

The most important component for surveillance of asymptomatic uterine cancer is physician history and physical with vaginal cytology, as the vaginal cuff is the most common site of recurrence. Cancer antigen (CA) 125 may be used if initially elevated. Advanced imaging is not indicated for surveillance. In a systematic review by Fung et al., the overall risk of recurrence was 13% for all patients and 3% or less for patients at low risk. Approximately 70% of all recurrences were symptomatic. Detection of asymptomatic recurrences ranged from 5% to 33% of patients with physical examination, 15% with CA 125, 0% to 14% with chest X-ray, and 5% to 21% with CT abdomen and pelvis. In a retrospective study, recurrences in high-grade endometrial carcinomas were discovered by symptoms 56% of the time and physical exam 18% of the time. Surveillance CT only detected 15% of asymptomatic recurrences. Limited data is available for MRI and PET/CT in surveillance of asymptomatic patients. In a small prospective study, PET detected asymptomatic uterine
cancer recurrence in only 4% of patients. A retrospective study evaluating adherence to Society of Gynecological Oncology guidelines resulted in an appreciable decline in CT imaging, CA 125, and clinical exams with no effect on outcomes. The National Comprehensive Cancer Network, American College of Radiology, and Society of Gynecologic Oncology do not recommend routine use of surveillance imaging for uterine cancer.

**ESOPHAGEAL CANCER**

For initial diagnosis, PET is generally not considered for detecting primary esophageal tumors, and evidence is lacking in its ability to differentiate between esophageal cancer and benign conditions.

**Systematic Reviews**

Kroese et al (2018) conducted a systematic review of the use of FDG-PET and FDG-PET/CT for detecting interval metastases following neoadjuvant therapy in patients with esophageal cancer. The literature search identified 14 studies for inclusion. The QUADAS tool was used to assess quality, with most studies rated moderate. The pooled proportion of patients with true distant metastases as detected by FDG-PET and FDG-PET/CT was 8% (95% CI, 5% to 13%). The pooled proportion of patients with false-positive distant findings was 5% (95% CI, 3% to 9%).

Cong et al (2016) published a meta-analysis evaluating the predictive value of FDG-PET and FDG-PET/CT for tumor response during or after neoadjuvant chemoradiotherapy in patients with esophageal cancer. The literature search, conducted through January 2016, identified 4 studies (n=192 patients) in which PET or PET/CT was performed during neoadjuvant chemoradiotherapy and 11 studies (n=490 patients) in which PET or PET/CT was performed after neoadjuvant chemoradiotherapy. All studies scored between 9 and 12 using the QUADAS tool. Pooled sensitivity and specificity for PET and PET/CT performed during neoadjuvant chemoradiotherapy were 85% (95% CI, 76% to 91%) and 59% (95% CI, 48% to 69%), respectively. Pooled sensitivity and specificity for PET and PET/CT performed after neoadjuvant chemoradiotherapy were 67% (95% CI, 60% to 73%) and 69% (95% CI, 63% to 74%), respectively.

Goense et al (2015) published a systematic review evaluating FDG-PET and PET/CT for the detection of recurrent esophageal cancer after treatment with curative intent. The literature search, conducted through December 2014, identified 8 studies (total N=486 patients) for inclusion. The quality of the studies was considered reasonable using the QUADAS tool, with low risk of bias for most studies, and high risk of bias in a few studies for patient selection. Pooled estimates of sensitivity and specificity of FDG-PET and FDG-PET/CT combined were 96% (95% CI, 93% to 97%) and 78% (95% CI, 66% to 86%), respectively. Subgroup analysis by technique (PET alone and PET/CT) was not possible for sensitivity due to heterogeneity. Specificity subgroup analysis showed no statistical difference between PET alone and PET/CT in detecting recurrent esophageal cancer.

In a meta-analysis of 245 patients with esophageal cancer from 6 studies, Shi et al (2013) reported that, for detection of regional nodal metastases, FDG-PET/CT had a sensitivity of 55% (95% CI, 34% to 74%) and specificity of 76% (95% CI, 66% to 83%), respectively.

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
An NCCN report conducted by Podoloff et al (2009) found studies showing that PET is more sensitive than other diagnostic imaging in detecting stage IV disease with distant lymph node involvement. A meta-analysis described in the report found a 67% pooled sensitivity, 97% specificity, and small added value after conventional staging in detecting distant metastasis.

Another use of PET in esophageal cancer is in determining whether to continue chemotherapy for potentially curative resection. The NCCN report by Podoloff described several studies in which response to chemotherapy, defined as a decline in standardized uptake values, correlated with long-term survival. Patients who do not respond to chemotherapy might benefit from this test by being spared futile and toxic chemotherapy. However, the treatment strategy of PET-directed chemotherapy does not appear to have been validated with RCTs showing improved net health outcome.

Guidelines
Current NCCN guidelines for esophageal cancer (v.2.2018) indicate that PET/CT can be considered under the following conditions:

- Part of the initial workup if there is no evidence of M1 disease.
- To assess response to preoperative or definitive chemoradiation.
- For staging purposes, prior to surgery to obtain nodal distribution information.

There is no discussion on the use of PET/CT for surveillance. The guidelines note that PET/CT for these indications is preferable to PET alone.

Section Summary: Esophageal Cancer
Evidence for PET or PET/CT to detect metastases, predict tumor response to treatment, or to detect recurrence in patients with esophageal cancer consists of meta-analyses. The meta-analyses have shown high sensitivity and specificity estimates for these indications. The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis and staging and restaging of esophageal cancer.

The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of esophageal cancer.

GASTRIC CANCER
Systematic Reviews
A systematic review by Li et al (2016) evaluated FDG-PET and FDG-PET/CT for detecting recurrent gastric cancer. The literature search, conducted through February 2015, identified 14 studies (total N=828 patients) for analysis. The analysis combined both imaging techniques; 3 studies used PET alone and 11 studies used PET/CT. Pooled sensitivity and specificity were 85% (95% CI, 75% to 92%) and 78% (95% CI, 72% to 84%), respectively.

In a meta-analysis, Zou and Zhou (2013) evaluated studies published through May 2013 and calculated the sensitivity and specificity of FDG-PET/CT for detecting recurrence of gastric cancer after surgical resection.
Eight studies (total N=500 patients) were eligible for the meta-analysis. The studies fulfilled 12 of the 14 QUADAS criteria for methodologic quality. Pooled sensitivity was 86% (95% CI, 71% to 94%) and pooled specificity was 88% (95% CI, 75% to 94%), respectively.

A systematic review by Wu et al (2012) pooled 9 studies (total N=562 patients) published through July 2011 that used FDG-PET alone for evaluating recurrent gastric cancer. Each selected study fulfilled at least 9 of the 14 criteria in the QUADAS tool for methodologic quality. Pooled sensitivity and specificity were 78% (95% CI, 68% to 86%) and 82% (95% CI, 76% to 87%), respectively. Reviewers concluded that PET/CT might be more effective than either PET alone or CT alone, but it was unclear what sources reviewers used for their estimates for PET/CT and CT alone.

**Guidelines**

Current NCCN guidelines for gastric cancer (v.2.2018) indicate that PET/CT (but not PET alone) can be used as part of an initial workup if there is no evidence of metastatic disease. The guidelines note that the sensitivity of PET/CT is lower than for CT alone due to low tracer accumulation in diffuse and mucinous tumor types, but specificity is higher. PET/CT adds value to the diagnostic workup with higher accuracy in staging (identifying tumor and pertinent nodal groups). NCCN guidelines also indicate that PET/CT can be used to evaluate response to treatment, in cases of renal insufficiency or allergy to CT contrast. There is no discussion on the use of PET/CT for surveillance.

**Section Summary: Gastric Cancer**

Evidence for the use of PET to diagnose recurrent gastric cancer consists of meta-analyses. One meta-analysis evaluated FDG-PET alone, one evaluated FDG-PET/CT, and another combined the 2 techniques into a single estimate. Sensitivity estimates ranged from 78% to 85% and specificity estimates ranged from 78% to 88%. The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis and staging, and restaging of gastric cancer.

The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of gastric cancer.

**HEAD AND NECK CANCER**

**Systematic Reviews**

A meta-analysis by Chen et al (2016) compared MRI, CT, and FDG-PET/CT in the detection of local and metastatic nasopharyngeal carcinomas. A literature search, conducted through April 2015, identified 23 studies (total N=2413 patients) for inclusion. Table 4 summarizes the results of the meta-analysis.

**Pooled Diagnostic Performance of FDG-PET/CT, Magnetic Resonance Imaging, and CT Alone in the Detection of Nasopharyngeal Carcinomas**
A meta-analysis by Wei et al (2016) compared diagnostic capabilities of FDG-PET/CT, MRI, and single-photon emission computed tomography in patients with residual or recurrent nasopharyngeal carcinoma. The literature search, conducted through December 2014, identified 17 studies for inclusion. All studies scored at least 9 of 14 in the QUADAS tool. Pooled sensitivity and specificity for F-FDG-PET/CT (n=12 studies) were 90% (95% CI, 85% to 94%) and 93% (95% CI, 90% to 95%), respectively. Pooled sensitivity and specificity for single-photon emission computed tomography (n=8 studies) were 85% (95% CI, 77% to 92%) and 91% (95% CI, 85% to 95%), respectively. Pooled sensitivity and specificity for MRI (n=9 studies) were 77% (95% CI, 70% to 83%) and 76% (95% CI, 73% to 79%), respectively.

Two meta-analyses evaluated FDG-PET or FDG-PET/CT in the detection of residual or recurrent head and neck cancer at various times following treatment. Results from these analyses are summarized in Table 5.

Table 5. Pooled Diagnostic Performance of FDG-PET or Dg-PET/CT in the Detection of Head and Neck Cancer

<table>
<thead>
<tr>
<th>Indication</th>
<th>No. of Studies (Patients)</th>
<th>Sensitivity (95% CI), %</th>
<th>Specificity (95% CI), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cheung et al (2016)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Residual/recurrent at primary site</td>
<td>18 (805)</td>
<td>86 (80 to 91)</td>
<td>82 (79 to 85)</td>
</tr>
<tr>
<td>Residual/recurrent at neck nodes</td>
<td>15 (726)</td>
<td>72 (63 to 80)</td>
<td>88 (85 to 91)</td>
</tr>
<tr>
<td>Recurrent at distant metastases</td>
<td>3 (184)</td>
<td>85 (65 to 96)</td>
<td>95 (90 to 98)</td>
</tr>
<tr>
<td>Local residual/recurrent, &lt;12 wk since therapy</td>
<td>NR</td>
<td>85 (75 to 92)</td>
<td>80 (76 to 83)</td>
</tr>
</tbody>
</table>
A systematic review by Sheikhbahaei et al (2015) calculated the predictive value of intratherapy or posttherapy FDG-PET or FDG-PET/CT for overall survival (OS) and event-free survival. The literature search, conducted through November 2014, identified 9 studies (N=600 patients) for inclusion in OS calculations and 8 studies (N=479 patients) for inclusion in event-free survival calculations. Patients with a positive scan had significantly worse OS than patients with negative scans (hazard ratio, 3.5; 95% CI, 2.3 to 5.4). The pooled hazard ratio for event-free survival was 4.7 (95% CI, 2.6 to 8.6). Relative risks at 2 years and at 3-to-5 years for death and recurrence or progression were calculated, based on the timing of FDG-PET or FDG-PET/CT (see Table 6).

Table 6. Pooled Diagnostic Performance of FDG-PET or FDG-PET/CT in the Detection of Head and Neck Cancer

<table>
<thead>
<tr>
<th>Outcome</th>
<th>No. of Studie s</th>
<th>2-Year RR (95% CI)</th>
<th>No. of Studie s</th>
<th>3- to 5-Year RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Final FDG-PET or FDG-PET/CT</td>
<td>6</td>
<td>8.3 (3.8 to 18.0)</td>
<td>6</td>
<td>2.2 (1.6 to 3.2)</td>
</tr>
<tr>
<td>FDG-PET or FDG-PET/CT, &lt;12 wk posttreatment</td>
<td>8</td>
<td>3.0 (1.9 to 4.6)</td>
<td>4</td>
<td>2.0 (1.3 to 3.2)</td>
</tr>
<tr>
<td>FDG-PET or FDG-PET/CT, ≥12 wk posttreatment</td>
<td>3</td>
<td>8.5 (4.0 to 18.3)</td>
<td>6</td>
<td>2.8 (1.9 to 4.0)</td>
</tr>
<tr>
<td>Recurrence or progression</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Final FDG-PET or FDG-PET/CT</td>
<td>6</td>
<td>5.2 (3.3 to 8.3)</td>
<td>5</td>
<td>2.6 (1.7 to 4.1)</td>
</tr>
</tbody>
</table>
Meta-analyses in 2013, 2014, and 2018 reported good sensitivities and specificities with FDG-PET/CT for diagnosing head and neck squamous cell cancers (better than CT and MRI) and for detecting head and neck cancer metastases (better than bone scintigraphy) and recurrence.

Additional meta-analyses by Li et al (2017) and Lin et al (2017) have reported that higher values of standard uptake value, metabolic tumor volume, and total lesion glycolysis from FDG-PET/CT might predict a poorer prognosis for patients with nasopharyngeal cancer.

Among the 3 studies identified in the TEC Assessment (2000) that used other diagnostic modalities to identify a primary tumor in patients with positive cervical lymph nodes, PET found more primary tumors than the other modalities in 2 studies and identified similar proportions in the third. When data from these 3 studies were pooled, PET was found to identify a tumor in 38% of cases and other modalities in 21% of cases.

When PET was used to stage cervical lymph nodes initially, the addition of PET to other imaging modalities increased the proportion of patients correctly staged, as confirmed histologically. When compared directly with other imaging modalities, pooled data from several studies has suggested that PET has a better diagnostic performance than CT and MRI. Of 8 studies focusing on the use of PET to detect residual or recurrent disease, 5 found PET to be more specific and sensitive, 2 reported mixed or equivalent results, and 1 reported worse results compared with CT.

Guidelines
Current NCCN guidelines on head and neck cancer (v.2.2018) indicate that PET/CT can be appropriate for stage III or IV disease evaluation, for detection of metastases or recurrence, and for evaluation of response to treatment (at a minimum of 12 weeks posttreatment to reduce false-positive rate). There is no discussion on the use of PET/CT for surveillance.

Section Summary: Head and Neck Cancer
Evidence for the use of FDG-PET/CT in the management of patients with head and neck cancer consists of systematic reviews and meta-analyses. In patients with head and neck cancers, PET or PET/CT is better able to detect local and metastatic disease than other imaging techniques. Evidence has also shown that FDG-PET/CT may be useful in predicting response to therapy. The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis and staging, and restaging of head and neck cancer.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of head and neck cancer.

KIDNEY CANCER/RENAL CELL CARCINOMA
Kidney cancer is the sixth most common cancer in men and the tenth most common cancer in women. The most common tumor type is renal cell carcinoma, which arises from the renal parenchyma. Primary nephrectomy is indicated in most forms of kidney cancer. Until recently, fully resected renal cell carcinoma has been managed with surveillance only. Treatment options for metastatic renal cell carcinoma have greatly expanded in the last decade with immunosuppressive therapies such as cell cycle checkpoint inhibitors (PD-1 agents), mechanistic target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKI).

INITIAL TREATMENT STRATEGY
Kidney cancer is staged using the American Joint Committee on Cancer TNM system. In a study comparing triphasic helical CT and fast MRI, renal cell carcinoma was correctly staged 67% of the time. In another prospective study, accuracy of MRI was 78%-87%, and the accuracy of CT was 80%-83%. Both modalities, however, are poor at detecting invasion of perinephric fat and assessing tumor extension into the renal veins or inferior vena cava. For the evaluation of renal vein involvement, MRI and CT appear to have approximately the same accuracy of 72%-76% and 78%-88%, respectively.

In the evaluation of primary renal cell carcinoma, PET accuracy was only 50%. The utility of PET/CT is adversely affected by poor FDG avidity and background uptake from the kidney. Although a poor staging modality, specificity of PET was found to approach 100% in 2 separate studies. Current evidence suggests that imaging of the pelvis is of low yield and does not affect overall management. For chest imaging, radiography is preferred, although CT is more sensitive in patients with symptoms, advanced-stage disease, anemia, or thrombocytopenia.

SUBSEQUENT TREATMENT STRATEGY
A pooled analysis of 15 studies found PET/CT to have combined sensitivity of 86% and specificity of 88%. Comparison across studies found similar sensitivity but markedly higher specificity with PET imaging.

LUNG CANCER
PET scanning may have a clinical role in patients with solitary pulmonary nodules for whom a diagnosis is uncertain after CT scan or chest radiograph. Younger patients who have no smoking history have a relatively low risk for lung cancer and, in this setting, the NPV of a PET scan is relatively high. If presented with a negative PET scan and information about the very low probability of undetected malignancy, it is quite likely that some patients would choose to avoid the harms of an invasive sampling procedure (ie, biopsy). A meta-analysis by Barger et al (2012) evaluating pulmonary nodules using dual-time PET (a second scan added after a delay) found that its additive value relative to a single PET scan is questionable.

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Non-Small-Cell Lung Cancer

In patients with known non-small-cell lung cancer (NSCLC), the clinical value of PET scanning relates to improved staging information regarding the involvement of mediastinal lymph nodes, which generally excludes patients from surgical excision. A TEC Assessment (1997) discussed a decision analysis that suggested the use of CT plus PET scanning in staging mediastinal lymph nodes resulted in fewer surgeries and an average gain in life expectancy of 2.96 days. This suggests that the reduction in surgeries was not harmful to patients.

Systematic Reviews

Brea et al (2018) conducted a systematic review comparing MRI, CT, FDG-PET, and FDG-PET/CT in differentiating metastatic and nonmetastatic lymph nodes. A meta-analysis was not conducted. Reviewers reported that most studies showed MRI had higher sensitivities, specificities, and diagnostic accuracy than CT and PET in determining malignancy of lymph nodes in patients with NSCLC.

A systematic review by Ruilong et al (2017) evaluated the diagnostic value of FDG-PET/CT for detecting solitary pulmonary nodules. The literature search, conducted to May 2015, identified 12 studies (1297 patients) for inclusion in the analysis. The pooled sensitivity and specificity of FDG-PET/CT to detect malignant pulmonary nodules are presented in Table 7.

Li et al (2017) conducted a meta-analysis of studies that compared FDG-PET/CT with gadolinium-enhanced MRI in the detection of brain metastases in patients with NSCLC. The literature search identified 5 studies (total N=941 patients) for inclusion. Study quality was assessed using criteria recommended by the Cochrane Methods Working Group, with scores ranging from 9 to 11 on the 12-point scale. Meta-analyses results are presented in Table 7.

He et al (2014) compared PET, PET/CT, and conventional imaging techniques for detecting recurrent lung cancer. Table 7 summarizes the diagnostic performances of the different imaging techniques:

Other meta-analyses have reported good sensitivities and specificities in the detection of lung cancer metastases and recurrence with PET/CT. A meta-analysis by Li et al (2013) calculated the sensitivity and specificity of PET/CT in the detection of distant metastases in patients with lung cancer and with NSCLC (see Table 7).

Table 7. Pooled Diagnostic Performance of Various Imaging Techniques in Patients With Lung Cancer

<table>
<thead>
<tr>
<th>Type of Imaging</th>
<th>Detection Measured</th>
<th>Sensitivity (95% CI), %</th>
<th>Specificity (95% CI), %</th>
<th>DOR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruilong et al</td>
<td>Solitary pulmonary nodules</td>
<td>82 (76 to 87)</td>
<td>81 (66 to 90)</td>
<td>18 (8 to 38)</td>
</tr>
<tr>
<td>(2017)</td>
<td>FDG-PET/CT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Li et al (2017)</td>
<td>Brain metastases</td>
<td>82 (76 to 87)</td>
<td>81 (66 to 90)</td>
<td>18 (8 to 38)</td>
</tr>
</tbody>
</table>

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Guidelines

Current NCCN guidelines for NSCLC (v.6.2018) indicate that PET/CT can be used in the staging of the disease, detection of metastases, treatment planning, and detection of disease recurrence. The guidelines note that PET is “best performed before a diagnostic biopsy site is chosen in cases of high clinical suspicion for aggressive, advanced-stage tumors.” However, PET is not recommended for detection of brain metastasis from lung cancers. While PET/CT is not routinely recommended for surveillance after completion of definitive therapy, it may be considered to differentiate between true malignancies and benign conditions (eg, atelectasis, consolidation, and radiation fibrosis), which may have been detected by CT imaging. If PET/CT detects recurrent disease, biopsy confirmation is necessary prior to initiating additional treatment because FDG remains avid up to 2 years.

The American College of Chest Physicians (2013) issued guidelines for the diagnosis and management of NSCLC. The guidelines stated that RCTs support the use of PET or PET/CT scanning as a component of lung cancer treatment and recommended PET or PET/CT for staging, detection of metastases, and avoidance of noncurative surgical resections.

Small-Cell Lung Cancer

Approximately 15% of all lung cancers are small-cell lung cancer (SCLC). Patients with SCLC are typically defined as having either limited stage or extensive stage disease. Most patients diagnosed with SCLC have extensive stage disease, which is characterized by distant metastases, malignant pericardial or pleural effusions, and/or contralateral hilar lymph node involvement. Limited stage SCLC is limited to the ipsilateral hemithorax and regional or mediastinal lymph nodes and can be encompassed in a safe radiotherapy field.

Systematic Reviews

A systematic review by Lu et al (2014) included 12 studies (total N=369 patients) of F-FDG-PET/CT for staging SCLC. Although estimated pooled sensitivity and pooled specificity were 98% (95% CI, 94% to 99%) and 98% (95% CI, 95% to 100%), respectively, included studies were small (median sample size, 22 patients); of primarily fair to moderate quality; and heterogeneous in design (retrospective, prospective). PET parameter
assessed, indication for PET, and reference standard used. It is not possible from the limited, poor quality evidence in this systematic review to determine whether the use of PET adds value relative to conventional staging tests for SCLC.

A systematic review by Ruben and Ball (2012) of staging SCLC found PET to be more effective than conventional staging methods; however, a limitation of this review is that the reviewers did not conduct a quality assessment of individual studies.

In an AHRQ review conducted by Seidenfeld et al (2006) evidence review that included 6 studies of patients with SCLC and non–brain metastases, PET plus conventional staging was more sensitive in detecting disease than conventional staging alone. PET may correctly upstage and downstage disease, and studies have reported very high occurrence of patient management changes attributed to PET. However, the quality of these studies was consistently poor, and insufficient detail in reporting was the norm, especially with respect to the reference standard.

Guidelines
Current NCCN guidelines for SCLC (v.2.2018) indicate PET/CT can be used in the staging of disease if limited stage is suspected. If extensive stage is established, brain imaging, MRI (preferred), or CT with contrast is recommended. PET/CT “is not recommended for routine follow-up.”

Section Summary: Lung Cancer
Evidence for PET or PET/CT in patients with NSCLC consists of meta-analyses. The meta-analyses have shown that use of PET or PET/CT in patients with lung cancer can aid in the diagnosis, staging, as well as detecting metastases and recurrence. The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis and staging and restaging of NSCLC.

The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of NSCLC.

Evidence for PET or PET/CT for patients with SCLC consists of systematic reviews and meta-analyses. These reviews have shown potential benefits in using PET for staging, though the quality of the studies was low. The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis, staging, and restaging of SCLC. Guidelines support the use of PET/CT if limited stage is suspected. If extensive stage is established, other imaging techniques (MRI or CT with contrast) are preferred.

The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of SCLC.

LYMPHOMA, INCLUDING HODGKIN DISEASE

Systematic Reviews
Of the 14 studies reviewed in a TEC Assessment (1999), 3 compared PET with anatomic imaging in initial staging and restaging of patients with Hodgkin disease and non-Hodgkin lymphoma. Two of these studies
included data from both diseased and nondiseased sites for PET and CT. Both studies found PET had better overall diagnostic accuracy than CT. The third study addressed detection of diseased sites only and found PET to have a sensitivity similar to that of CT or MRI. Among the 6 studies that reported on concordance between PET and other imaging modalities, PET was discordant with other modalities in 11% to 50% of cases; PET was correct among discordances in 40% to 75% of cases. PET has been reported to affect patient management decisions in 8% to 20% of patients in 5 studies, mainly by correctly upstaging disease, but also by correctly downstaging disease. Thus, when PET is added to conventional imaging, it can provide useful information for selecting effective treatment appropriate to the correct stage of the disease.

Lymphoma Diagnosis
Meta-analyses have reported good sensitivities and specificities with PET/CT in the detection of newly diagnosed Hodgkin lymphoma (2014) and diffuse large B-cell lymphoma (2014).

Lymphoma Restaging
A systematic review and meta-analysis by Adams and Kwee (2016) evaluated the proportion of false-positive lesions at interim and end-of-treatment as detected by FDG-PET in patients with lymphoma. The literature search, conducted through January 2016, identified 11 studies (total N=139 patients) for inclusion. Study quality was moderate, as assessed by the QUADAS-2 tool. The weighted summary proportion of false-positive results among all biopsied lesions both during and after completion of treatment was 56% (95% CI, 33% to 77%). Subgroup analyses found the following FDG-PET false-positive proportions for: interim non-Hodgkin lymphoma (83%; 95% CI, 72% to 90%); end-of-treatment non-Hodgkin lymphoma (31%; 95% CI, 4% to 84%), and end-of-treatment Hodgkin lymphoma (23%; 95% CI, 5% to 65%). No studies calculating the false-positive rate for interim Hodgkin lymphoma were identified.

A systematic review by Adams et al (2015) focused on the outcomes of patients with Hodgkin lymphoma who had negative residual mass after FDG-PET scanning. When a persistent mass is non-FDG-avid, the patient is considered to be in complete remission, though the significance of having a residual mass is unclear. The literature search, conducted through December 2014, identified 5 studies (total N=727 patients) for inclusion. Follow-up of patients in the studies ranged from 1 to 13 years. The pooled relapse proportion was 6.8% (95% CI, 2.6% to 12.5%).

Lymphoma Management
Systematic Reviews
Another systematic review by Adams and Kwee (2017) evaluated the prognostic value of FDG-PET in patients with refractory or relapsed Hodgkin lymphoma considering autologous cell transplantation. The literature search, conducted through May 2016, identified 11 studies (total N=664 patients) for inclusion. In general, the overall quality of selected studies was poor, based on Quality in Prognosis Studies (QUIPS). Pooled sensitivity and specificity of pretransplant 18F-FDG-PET in predicting treatment failure were 54% (95% CI, 44% to 63%) and 73% (95% CI, 67% to 79%), respectively. Pooled sensitivity and specificity of
pretransplant FDG-PET in predicting death after treatment were 55% (95% CI, 39% to 70%) and 69% (95% CI, 61% to 76%), respectively.

A meta-analysis by Adams and Kwee (2016) evaluated the prognostic value of FDG-PET in patients with aggressive non-Hodgkin lymphoma considering autologous cell transplantation. The literature search, conducted through July 2015, identified 11 studies (total N=745 patients) for inclusion. The overall quality of selected studies was moderate, based on QUIPS criteria. Patients with positive pretransplant FDG-PET results had progression-free survival (PFS) rates ranging from 0% to 52%. Patients with negative pretransplant FDG-PET results had PFS rates ranging from 55% to 85%. OS was 17% to 77% in patients with positive FDG-PET results and 78% to 100% in patients with negative FDG-PET results. Based on 5 studies, pooled sensitivity and specificity of pretransplant FDG-PET predicting treatment failure (defined as progressive, residual, or relapsed disease) were 67% (95% CI, 58% to 75%) and 71% (95% CI, 64% to 77%), respectively.

A systematic review by Zhu et al (2015) evaluated the prognostic value of FDG-PET in patients with diffuse B-cell lymphoma treated with rituximab-based immune chemotherapy. The literature search identified 11 studies (N=1081) for inclusion. The pooled hazard ratio comparing PFS of patients with positive interim FDG-PET results and negative interim FDG-PET results was 3.0 (95% CI, 2.3 to 3.9). Patients with a negative interim FDG-PET result had a higher complete remission rate than patients with a positive interim FDG-PET result (relative risk, 5.5; 95% CI, 2.6 to 11.8).

Randomized Controlled Trials
Borchmann et al (2017) reported on an open-label phase 3 RCT by the German Hodgkin Study Group, which randomized patients newly diagnosed with advanced Hodgkin lymphoma to different levels of eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), based on PET results. After 2 cycles of eBEACOPP, PET-positive patients were randomized to 6 more cycles of eBEACOPP (n=217) or eBEACOPP plus rituximab (n=217). PET-negative patients were randomized to 6 more cycles of eBEACOPP (n=504) or 4 more cycles of eBEACOPP (n=501). Five-year PFS rates for the PET-positive 6-cycle eBEACOPP and 6-cycle eBEACOPP plus rituximab arms were 90% (95% CI, 85% to 94%) and 88% (95% CI, 83% to 93%), respectively. Five-year PFS rates for the PET-negative 6-cycle and 4-cycle arms were 91% (95% CI, 88% to 94%) and 92% (95% CI, 89% to 95%), respectively. Results showed that PET-negative patients can receive fewer cycles of treatment without a negative impact on PFS and that PET-positive patients do not need an intensified treatment (addition of rituximab) to improve PFS.

Guidelines
Current NCCN guidelines for Hodgkin lymphoma (v.3.2018) and non-Hodgkin lymphomas (v.4.2018) indicate that PET/CT may be used in the diagnostic workup, staging, restaging, and evaluating treatment response. The guidelines recommend using the internationally recognized Deauville 5-point PET scale for initial staging and assessment of treatment response. The following PET/CT results are assigned the corresponding scores: 1=no uptake; 2=uptake ≤ mediastinum; 3=uptake > mediastinum but ≤ liver; 4=uptake moderately higher than liver; and 5=uptake markedly higher than liver and/or new lesions. The Deauville PET scores can be used to
determine the course of treatment. The guidelines note that if PET/CT detects 3 or more skeletal lesions, the marrow may be assumed to be involved and marrow biopsies are no longer indicated. The guidelines also note “Surveillance PET should not be done routinely due to risks for false positives. Management decisions should not be based on PET scan alone; clinical or pathologic correlation is needed.”

Section Summary: Lymphoma, Including Hodgkin Disease
Evidence for the use of FDG-PET/CT in the management of patients with lymphoma consists of systematic reviews and meta-analyses. In patients with lymphoma, PET can provide information for staging or restaging. Evidence has also shown that FDG-PET/CT can be useful in predicting response to therapy in patients with lymphoma. The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis and staging, and restaging of Hodgkin lymphoma and non-Hodgkin lymphoma.

The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of Hodgkin lymphoma and non-Hodgkin lymphoma.

MELANOMA
Surgical resection for melanoma is limited to those with local disease. Patients with widespread disease are not candidates for resection. Frequently, there is microscopic spread of cancer cells to the proximal lymph nodes. Therefore, patients with a high risk of nodal spread, as assessed by the thickness of the primary melanoma, may be candidates for lymph node sampling, termed sentinel node biopsy. PET scanning has been investigated both as a technique to detect widespread disease as part of an initial staging procedure and to evaluate the status of local lymph nodes to determine the necessity of sentinel node biopsy. To consider PET as a useful alternative to sentinel node biopsy, it must have high sensitivity and specificity when sentinel node biopsy or lymph node dissection serves as the reference standard. In the only study of this kind, PET had a sensitivity of only 17%, suggesting that PET rarely detects small metastases that can be discovered by sentinel node biopsy. Thus, a TEC Assessment (1999) concluded that PET is not as beneficial as sentinel node biopsy for assessing regional lymph nodes.

“The intent of using PET to detect extranodal metastases is to aid in selecting treatment appropriate to the patient’s extent of disease…. It may be inferred from [the evidence] that PET was usually correct when discordant with other modalities. PET affects management in approximately 18% of patients.”

Systematic Reviews
In meta-analysis of 9 studies (total N=623 patients), Rodriguez Rivera et al (2014) reported pooled sensitivity and specificity of FDG-PET for detecting systemic metastases in patients with stage III cutaneous melanoma of 89% (95% CI, 65% to 98%) and 89% (95% CI, 77% to 95%), respectively.

Guidelines
Current NCCN guidelines for melanoma (v.3.2018) indicate that PET/CT can be used for staging and restaging more advanced disease (eg, stage III) in the presence of specific signs and symptoms. PET/CT is not recommended for stage I or II disease. PET/CT also is listed as an option for surveillance screening for...
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

recurrence every 3 to 12 months (category 2B) at the physician’s discretion. Because most recurrences occur within the first 3 years, routine screening for asymptomatic recurrence is not recommended beyond 3 to 5 years. The guidelines note that the safety of PET/CT is of concern due to cumulative radiation exposure.

Section Summary: Melanoma
Evidence for the use of FDG-PET/CT in the management of patients with melanoma consists of a TEC Assessment, systematic reviews, and meta-analyses. In patients with melanoma, PET can provide information for staging or restaging in patients with more advanced disease (stage III or higher). The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis and staging and restaging of stage III or IV melanoma.

The evidence does not support the use of FDG-PET and FDG-PET/CT for the diagnosis or staging and restaging of stage I or II melanoma.

The evidence supports the use of FDG-PET and FDG-PET/CT for surveillance of melanoma.

MERKEL CELL CARCINOMA
Merkel cell carcinoma is a very rare and aggressive type of skin cancer arising from cells in the basal layer of the epidermis and hair follicles. Incidence increases with age and is higher in Caucasians; other risk factors include sun exposure, immunosuppression, and Merkel cell polyomavirus.

INITIAL AND SUBSEQUENT TREATMENT STRATEGIES
Merkel cell carcinoma is staged using the American Joint Committee on Cancer TNM system. Merkel cell carcinoma is a highly aggressive cancer and up to 8% of patients will present with metastases. Results from a single institution study showed that PET resulted in upstaging in 17% and downstaging in 5% of patients with an overall management change in 37% of patients. A second single institution study also found that PET resulted in upstaging of 16% of patients. A meta-analysis of 6 studies (N = 92 patients) showed PET had a sensitivity of 90% (95% CI, 80%-96%) and specificity of 98%. Asymptomatic brain metastases are fairly rare and routine use of MRI is not recommended.

MULTIPLE MYELOMA
Systematic Reviews
Two systematic reviews, one of which also conducted a meta-analysis, addressed PET for the staging of multiple myeloma.

Lu et al (2012) included 14 studies (N=395 patients) and reported pooled estimates of sensitivity and specificity of 96% (95% CI, 80% to 100%) and 78% (95% CI, 40% to 95%), respectively, in the detection of extramedullary lesions in patients with multiple myeloma.
Van Lammeren-Venema et al (2012) included 18 studies (N=798 patients) in a systematic review that compared FDG-PET with whole body x-ray in staging and response assessment of patients with multiple myeloma. Using the QUADAS tool to assess quality, the studies received a mean percentage of the maximum score of 61%. Reviewers reported that, in general, FDG-PET is more sensitive than whole body x-ray in detecting myeloma bone lesions.

Guidelines
Current NCCN guidelines for multiple myeloma (v.1.2019) added PET/CT to the list of imaging techniques that may be useful under certain circumstances, to discern active from smoldering myeloma, particularly if the skeletal survey is negative. PET/CT may also be considered to detect disease progression.

Section Summary: Multiple Myeloma
Evidence for the use of PET or PET/CT in the management of patients with multiple myeloma consists of systematic reviews and a meta-analysis. The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis, staging, and restaging. The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of multiple myeloma.

NEUROENDOCRINE TUMORS

Systematic Reviews

68Ga-PET and 68Ga-PET/CT
Barrio et al (2017) conducted a systematic review and meta-analysis on the impact of gallium 68 (68Ga) PET/CT on management decisions in patients with neuroendocrine tumors. Reviewers selected 14 studies (N=1561 patients). Change in management occurred in 44% of the patients following 68Ga-PET/CT. Clinical outcomes were not reported.

Deppen et al (2016) conducted a systematic review assessing the use of 68Ga-PET/CT for the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors. Seventeen studies (total N=971 patients) were included in the analysis. Comparators differed among the studies: octreotide and conventional imaging (3 studies), other radiopharmaceuticals without direct imaging comparators (5 studies), and conventional imaging (9 studies). Meta-analysis of the 9 studies that compared 68Ga-PET/CT scanning with conventional imaging resulted in a sensitivity of 91% (95% CI, 81% to 96%) and a specificity of 91% (95% CI, 78% to 96%).

Two meta-analyses from Treglia et al (2012) addressed the use of PET in patients with neuroendocrine tumors. One report included patients with thoracic and gastroenteropancreatic neuroendocrine tumors who had imaging with PET using 68Ga-PET and 68Ga-PET/CT. Sixteen studies (total N=567 patients) were included in the analysis. The studies were considered medium to high quality, based on an assessment using the QUADAS tool. Meta-analysis showed a sensitivity and specificity of 93% (95% CI, 91% to 95%) and 91%
18F-DOPA PET and 18F-DOPA PET/CT
The other meta-analysis included studies of patients with paragangliomas scanned by PET with fluorine 18-dihydroxyphenylalanine (18F-DOPA) PET and 18F-DOPA PET/CT. Eleven studies (total N=275 patients) were analyzed. The QUADAS tool was used to assess quality: 2 studies had a B rating, 4 a C rating, and 5 a D rating. Reference standards varied across studies, with 2 using MRI, 3 using histology on all patients, and the remaining using histology only when feasible. Meta-analysis showed a sensitivity and specificity of 91% (95% CI, 87% to 94%) and 79% (95% CI, 76% to 81%), respectively.

Guidelines
Current NCCN guidelines for neuroendocrine tumors (v.2.2018) have recommended somatostatin receptor-based imaging with PET/CT, using 68Ga-dotatate as the radioactive tracer. The guidelines note that 68Ga-PET/CT is more sensitive than somatostatin receptor scintigraphy for determining somatostatin receptor status. 68Ga-PET/CT is recommended for diagnosis, staging, and restaging. FDG-PET may be considered in poorly differentiated carcinomas only in biopsy proven neuroendocrine tumors of unknown primary. Neither 68Ga-PET/CT nor FDG-PET are recommended for surveillance. 18F-DOPA PET/CT is not discussed in the guidelines.

Section Summary: Neuroendocrine Tumors
Evidence for the use of PET or PET/CT in the management of patients with neuroendocrine tumors consists of meta-analyses. Two different radiopharmaceuticals were used: FDG-PET/CT and 68Ga-PET/CT. Meta-analyses of studies using 68Ga-PET/CT as the radiotracer for diagnosis and staging of neuroendocrine tumors report relatively high sensitivities and specificities compared with conventional imaging techniques.

The evidence does not support the use of FDG-PET/CT for the diagnosis, staging, and restaging, or surveillance of neuroendocrine tumors.

The evidence does not support the use of FDG-PET/CT for surveillance of neuroendocrine tumors.

The evidence supports the use of 68Ga-PET/CT for the diagnosis, staging, and restaging of neuroendocrine tumors.

The evidence does not support the use of 68Ga-PET/CT for surveillance of neuroendocrine tumors.

OVARIAN CANCER
For primary evaluation (ie, suspected ovarian cancer), the ability to rule out malignancy with a high NPV would change management by avoiding unnecessary exploratory surgery. However, available studies have suggested that PET scanning has a poorer NPV than other options, including transvaginal ultrasound, Doppler studies, or MRI. Adding PET scanning to ultrasound or MRI did not improve results.
Positive predictive value is of greatest importance in evaluating patients with known ovarian cancer, either to detect disease recurrence or progression or to monitor response to treatment.

**Systematic Reviews**

A meta-analysis by Xu et al (2017) evaluated the diagnostic value of PET and PET/CT for recurrent or metastatic ovarian cancer. The literature search, conducted through August 2014, identified 64 studies for inclusion: 15 studies (n=657 patients) using PET and 49 studies (n=3065 patients) using PET/CT. The pooled sensitivity and specificity for PET were 89% (95% CI, 86% to 92%) and 90% (95% CI, 84% to 93%), respectively. The pooled sensitivity and specificity for PET/CT were 92% (95% CI, 90% to 93%) and 91% (95% CI, 89% to 93%), respectively. Subgroup analyses were conducted by study region (Asia, Europe, and America). For PET/CT, sensitivities in the Asia and Europe studies were significantly higher compared with the sensitivity in the America studies.

A meta-analysis by Limei et al (2013), included 28 studies (total N=1651 patients) published through December 2012; it evaluated the diagnostic value of PET/CT in suspected recurrent ovarian cancer Using the Oxford Evidence rating system for quality, 7 studies were considered high quality and 21 were low quality. Reviewers found PET/CT was useful for detecting ovarian cancer recurrence, with pooled sensitivity and specificity of 89% and 75% for the high-quality studies and 89% and 93% for the low-quality studies, respectively.

An AHRQ systematic review conducted by Matchar et al (2004) suggested that PET might have value for detecting recurrence when cancer antigen 125 is elevated and conventional imaging does not clearly show recurrence, this had not been demonstrated in an adequately powered prospective study. An AHRQ systematic review conducted by Ospina et al (2008) found that evidence supported the use of PET/CT for detecting recurrent ovarian cancer. Evidence for initial diagnosis and staging of ovarian cancer was inconclusive.

**Guidelines**

**American College of Radiology**

ACR Appropriateness Criteria (2018) on staging and follow-up of ovarian cancer have stated that PET/CT and MRI may be appropriate when lesions are indeterminate with contrast-enhanced CT.

**National Comprehensive Cancer Network**

Current NCCN guidelines for ovarian cancer (v.2.2018) indicate that PET/CT can be appropriate “for indeterminate lesions if results will alter management.” PET/CT may be considered for monitoring patients with stage II through IV ovarian cancer receiving primary chemotherapy if clinically indicated. PET/CT also can be considered if clinically indicated after complete remission, for follow-up and for monitoring for recurrence if CA-125 is rising or clinical relapse is suspected.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Section Summary: Ovarian Cancer
Evidence for PET and PET/CT for the initial diagnosis of ovarian cancer consists of an AHRQ systematic review (2014), which reported that the evidence is inconclusive. Evidence on the use of PET and PET/CT for the detection of ovarian cancer recurrence includes 2 meta-analyses and an AHRQ systematic review (2008). Pooled sensitivities and specificities support the use of PET and PET/CT for the detection of recurrent ovarian cancer. The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis and staging and restaging of esophageal cancer.

The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of ovarian cancer.

PANCREATIC CANCER

Systematic Reviews
A Cochrane review by Best et al (2017) compared the diagnostic accuracy of several imaging techniques (CT, MRI, PET, and endoscopic ultrasound) in detecting cancerous and precancerous lesions in the pancreas. The literature review, conducted through July 2016, identified 54 studies total, 10 using PET. Assessment of the selected studies found none to have high methodologic quality. A meta-analysis of 3 studies reported a sensitivity and specificity in diagnosing pancreatic cancer of 92% (95% CI, 80% to 97%) and 65% (95% CI, 39% to 84%), respectively. The positive predictive value and NPV (calculated by BCBSA) were 89% and 71%, respectively. Reviewers could not adequately compare the various techniques due to the imprecision of estimates, poor quality of studies, and heterogeneity in categorizing lesions.

Wang et al (2017) conducted a meta-analysis comparing CT alone, PET alone, and PET/CT in the preoperative assessment of patients with pancreatic cancer. The literature review identified 13 studies (total N=1343 patients). The Newcastle-Ottawa Scale was used to assess study quality, with scores ranging from 6 to 8 on the 9-point scale. PET alone was not superior to CT alone (pooled OR=1.0; 95% CI, 0.6 to 1.6) in detecting distant metastases. However, PET/CT was superior to CT alone (pooled OR=1.7; 95% CI, 1.3 to 2.1) in detecting distant metastases. Neither PET nor PET/CT was superior to CT alone in detecting lymph node invasion (pooled OR=1.0; 95% CI, 0.6 to 1.5).

In a meta-analysis of 9 studies (total N=526 patients), Rijkers et al (2014) reported pooled sensitivity and specificity of FDG-PET/CT for confirming suspected pancreatic cancer of 90% (95% CI, 87% to 93%) and 76% (95% CI, 66% to 84%), respectively. Two reviews on pancreatic carcinoma, conducted by Ospina et al (2008) and Podoloff et al (2009) have suggested that PET/CT can be useful for staging certain patients when the standard staging protocol is inconclusive.

Both the AHRQ systematic review by Matchar et al (2004) and the TEC Assessment (1999) focused on 2 clinical applications of PET scanning in patients with known or suspected pancreatic cancer: the use of PET to distinguish between benign or malignant pancreatic masses, and the use of PET as a staging technique in patients with known pancreatic cancer.
In terms of distinguishing between benign and malignant disease, the criterion standard is a percutaneous or open biopsy. If PET were to be used to allow patients with scans suggesting benign masses to avoid biopsy, a very high NPV would be required. The key statistic underlying the NPV is the false-negative rate. Patients with false-negative results are incorrectly considered to have benign disease and thus are not promptly treated for pancreatic cancer. Based on the TEC literature review, the NPV ranged between 75% and 92%, depending on an underlying prevalence of disease ranging from 50% to 75%. The TEC Assessment concluded that this level of diagnostic performance would not be adequate to recommend against biopsy. The Matchar AHRQ report found that sometimes PET was more accurate than other modalities, but a meta-analysis showed that it is unclear whether PET’s diagnostic performance would surpass decision thresholds for biopsy or laparotomy. In both the TEC and AHRQ reviews, data were inadequate to permit conclusions on the role of PET scanning as a technique to stage known pancreatic cancer.

Observational Studies
Ghaneh et al (2018) conducted the largest study to date, measuring the incremental diagnostic value of PET/CT when added to a standard diagnostic workup with multidetector CT. The study was a prospective nonrandomized study of 550 patients. Sensitivity and specificity were 88.5% and 70.6%, respectively, which was a significant improvement from CT alone. PET/CT also correctly changed staging in 56 patients, influenced management in 250 patients, and stopped resection in 58 patients scheduled for surgery.

Guidelines
Current NCCN guidelines for pancreatic cancer (v.2.2018) state "the role of PET/CT remains unclear... [PET/CT] may be considered after formal pancreatic CT protocol in high-risk patients to detect extra pancreatic metastasis. It is not a substitute for high-quality contrast-enhanced CT."

Section Summary: Pancreatic Cancer
Evidence for PET and PET/CT for the initial diagnosis of pancreatic cancer consists of a TEC Assessment, a Cochrane review, a meta-analysis, and a large observational study published subsequent to the reviews. The TEC Assessment reported that the NPVs in several studies were inadequate to influence the decision for a biopsy. Other reviews also noted limitations such as imprecise estimates and poor quality of studies. Studies published subsequent to the reviews also reported low NPVs. The large observational study, which assessed the incremental diagnostic value of PET/CT when added to standard workup with CT, showed significant improvements in sensitivity and specificity compared with CT alone.

The evidence supports the use of FDG-PET and FDG-PET/CT for suspected pancreatic cancer when results from other imaging techniques are inconclusive.

The evidence does not support the use of FDG-PET and FDG-PET/CT for the diagnosis, staging, and restaging, or surveillance of pancreatic cancer.
PARANEOPLASTIC SYNDROME
Paraneoplastic disease is a rare manifestation of cancer that is not related directly to tumor involvement, metastases, or metabolic derangements. Autoantibodies have been identified as a cause in up to 60% of the recognized syndromes attributed to paraneoplastic disease. In many cases, symptoms occur prior to discovery of the primary tumor. The most common presentations are neurologic (central or peripheral), but paraneoplastic disease also manifests in muscle and other soft tissue. The most common malignancies associated with paraneoplastic disease are small cell lung cancer, thymoma, and hematologic cancers.

INITIAL TREATMENT STRATEGY
PET/CT has been found to be more accurate than CT in the detection of occult malignancy associated with paraneoplastic syndrome. In a retrospective study, PET outperformed CT by 50%. The sensitivity and specificity of PET compared to CT were 80% and 67%, vs 30% and 71%, respectively. Another retrospective study from the same institution found that PET/CT detected an additional 18% of cancers in patients with CT-negative paraneoplastic disease. In a review and meta-analysis of 21 studies, PET imaging demonstrated high diagnostic accuracy and moderate to high sensitivity (81%) and specificity (86%) for detection of underlying malignancy in suspected paraneoplastic syndrome.

SURVEILLANCE
The benefit of advanced imaging for surveillance of paraneoplastic syndrome without an identified malignancy has not been demonstrated.

PENILE, VAGINAL, and VULVAR CANCERS
Vaginal, vulvar, and penile cancers are relatively uncommon, accounting for less than 1% of all cancers in the U.S. The most common histologic subtype is squamous cell carcinoma, although adenocarcinoma is also seen in the vagina.

Risk factors for developing genital cancers are human papillomavirus infection, human immunodeficiency virus infection, smoking, and exposure to diethylstilbestrol. The most common presentation is local symptoms such as bleeding, irritation, discharge, or skin changes.

INITIAL TREATMENT STRATEGY
Vaginal, vulvar, and penile cancers are staged using the American Joint Committee on Cancer TNM system. In a retrospective study, MRI performed prior to surgery for vulvar cancer had a local staging accuracy of 83% and an overall staging accuracy of 69.4%, which increased to 75%-85% when combined with CT. Comparable findings regarding the utility of MRI for the diagnosis, local staging, and spread of disease of vaginal cancer have been reported in 2 small studies. There is a lack of high-quality prospective studies evaluating PET/CT for staging vaginal and vulvar cancer. Cohn et al. found that PET/CT had sensitivity of 80%, specificity of 90%, and negative predictive value of 80% in identifying lymph node metastases; thus, PET/CT does not obviate the need for surgical staging. In the largest study (N = 50) comparing PET and conventional imaging data for vulvar and vaginal cancer, FDG PET/CT detected nodes suspicious for metastases in 35% of patients, as compared to MRI and CT, 13% and 7%, respectively. Distant metastases were seen in an
additional 4% when compared to conventional CT, and overall resultant change in management occurred in 36% of cases. In a small prospective study (N = 23) of patients with vaginal cancer, PET detected lymph node involvement in 35% of patients compared to 17% for CT alone.

For penile cancer, imaging is not indicated for low-risk disease (Tis, Ta, T1a). Distant metastatic disease is rare and occurs in less than 4% of cases without bulky disease. For intermediate to high risk (T1b, T2 or greater) and/or palpable inguinal lymph nodes, chest imaging should be performed in addition to CT abdomen and pelvis with contrast. Preoperative CT has a reported sensitivity of 95% and a specificity of 82%. In a study of 10 patients, MRI with lymphotropic nanoparticles had a sensitivity, specificity, positive predictive value, and negative predictive value of 100%, 97%, 81%, and 100%, respectively. There is insufficient data to support the routine use of PET/CT for staging of penile cancer. In a comparative study, the sensitivity of PET was 80% compared to 100% in MRI and specificities were equivalent. Another trial looking at 13 patients confirmed these findings. In a meta-analysis of 7 studies, PET had a pooled sensitivity and specificity of 80.9% and 92.4%. Sensitivity was 96.4% when inguinal lymph nodes were detected clinically, but fell to 56.5% when nodes were clinically negative.

SURVEILLANCE
As most recurrences of vulvar and vaginal cancer are local, surveillance imaging is not indicated. In concordance with both National Comprehensive Cancer Network and Society of Gynecologic Oncology guidelines, imaging should only be performed when recurrence is suspected based on symptoms or exam findings. For penile cancer, surveillance with CT may be performed for N2/3 disease, but is not indicated beyond 2 years.

CANCERS OF THE PLEURA, THYMUS, HEART, AND MEDIASTINUM
Cancers of the pleura, thymus, heart, and mediastinum represent a heterogeneous group of diseases that can be either benign or malignant. The most common malignancies in this group are malignant pleural mesothelioma, thymoma, and thymic carcinoma. Myasthenia gravis is a paraneoplastic syndrome often associated with thymic neoplasms. Patients with mediastinal masses often present with symptoms resulting from direct compression of mediastinal structures, which may include cough, shortness of breath, superior vena cava syndrome, or Horner’s syndrome. Malignant pleural mesothelioma may present with nonspecific pulmonary symptoms or systemic symptoms due to distant metastases.

INITIAL TREATMENT STRATEGY
MRI has been shown to be superior to CT for evaluating solitary foci of chest wall invasion, endothoracic fascial involvement, and diaphragmatic muscle invasion. MRI should be considered for suspected chest wall, spinal, diaphragmatic, or vascular involvement based on CT. Although not highly accurate at staging T4 disease or N2 lymphadenopathy, PET plays a role in detection of extra-thoracic disease, eliminating the need for surgery in 16%-40% of patients. For thymoma or thymic carcinoma, MRI chest may help differentiate benign cysts and thymoma from thymic carcinoma, thus avoiding the need for surgery. PET can be used for initial staging to differentiate low grade thymoma from FDG-avid thymic carcinoma. In a small number of patients (6%), PET identified unresectable metastatic disease not detected by CT. In a review of 14 studies,
PET/CT was able to consistently differentiate benign and malignant disease and detect extrathoracic metastases. Results were mixed regarding correlation with the Masaoka staging system for thymoma, which is based on tumor invasion and metastases.

**SUBSEQUENT TREATMENT STRATEGY**
The American Society for Clinical Oncology recommends CT with assessment of response of malignant pleural mesothelioma based on the RECIST criteria.

**PROSTATE CANCER**

**11C-Choline PET, 11C-Choline PET/CT, 18F-Fluciclovine PET**

**Prostate Cancer Diagnosis**
Liu et al (2016) and Ouyang et al (2016) conducted meta-analyses comparing the diagnostic accuracy of 4 radiotracers (FDG, carbon 11 choline [11C-choline], fluorine 18 fluorocholine [18F-FCH], and carbon 11 acetate) in detecting prostate cancer. The literature search for the Liu review, conducted through July 2015, identified 56 studies (total N=3586 patients) for inclusion. Using the QUADAS-2 system to evaluate study quality, reviewers determined that the studies were reliable, with scores of 6 to 9 out of 10. Pooled estimates for the 4 types of radiotracers are summarized below (see Table 8). The literature search for the Ouyang review included studies using elastography and was conducted through April 2015. Study quality was not addressed.

**Table 8. Pooled Diagnostic Performance of Different Radiotracers in Detecting Prostate Cancer**

<table>
<thead>
<tr>
<th>Imaging Technique</th>
<th>No. of Studies</th>
<th>Sensitivity % (95% CI)</th>
<th>Specificity % (95% CI)</th>
<th>AUC (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liu et al (2016)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11C-choline PET/CT</td>
<td>31</td>
<td>81 (77 to 88)</td>
<td>82 (73 to 88)</td>
<td>0.89 (0.86 to 0.91)</td>
</tr>
<tr>
<td>18F-FCH-PET/CT</td>
<td>15</td>
<td>76 (49 to 91)</td>
<td>93 (84 to 97)</td>
<td>0.94 (0.92 to 0.96)</td>
</tr>
<tr>
<td>11C-acetate PET/CT</td>
<td>5</td>
<td>79 (70 to 86)</td>
<td>59 (43 to 73)</td>
<td>0.78 (0.74 to 0.81)</td>
</tr>
<tr>
<td>FDG-PET/CT</td>
<td>5</td>
<td>67 (55 to 77)</td>
<td>72 (50 to 87)</td>
<td>0.73 (0.69 to 0.77)</td>
</tr>
<tr>
<td>Ouyang et al (2016)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elastographya</td>
<td>26</td>
<td>76 (68 to 83)</td>
<td>78 (72 to 83)</td>
<td>0.84</td>
</tr>
<tr>
<td>11C-choline PET/CT</td>
<td>31</td>
<td>78 (72 to 84)</td>
<td>79 (71 to 82)</td>
<td>0.85</td>
</tr>
<tr>
<td>18F-FCH-PET/CT</td>
<td>15</td>
<td>73 (54 to 87)</td>
<td>59 (41 to 75)</td>
<td>0.91</td>
</tr>
<tr>
<td>11C-acetate PET/CT</td>
<td>5</td>
<td>79 (68 to 86)</td>
<td>59 (41 to 75)</td>
<td>0.77</td>
</tr>
<tr>
<td>FDG-PET/CT</td>
<td>5</td>
<td>76 (68 to 83)</td>
<td>78 (72 to 83)</td>
<td>0.84</td>
</tr>
</tbody>
</table>

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Prostate Cancer Staging and Restaging

Systematic Reviews
A meta-analysis by Fanti et al (2016) assessed the accuracy of $^{11}$C-choline PET/CT in the restaging of prostate cancer patients with biochemical recurrence after initial treatment with curative intent. The literature search, conducted through December 2014, identified 12 studies (total N=1270 patients) for inclusion in the analysis. Pooled sensitivity and specificity were 89% (95% CI, 83% to 93%) and 89% (95% CI, 73% to 96%), respectively.

In a meta-analysis by von Eyben and Kairemo (2014), the pooled sensitivity and specificity of $^{11}$C-choline PET/CT for detecting prostate cancer recurrence in 609 patients were 62% (95% CI, 51% to 66%) and 92% (95% CI, 89% to 94%), respectively. In an evaluation of 280 patients from head-to-head studies comparing choline PET/CT with bone scans, PET/CT identified metastases significantly more often than did bone scanning (127 [45%] vs 46 [16%], respectively; odds ratio, 2.8; 95% CI, 1.9 to 4.1; p<0.001). Reviewers also reported that $^{11}$C-choline PET/CT changed treatment in 381 (41%) of 938 patients. Complete prostate-specific antigen (PSA) response occurred in 101 (25%) of 404 patients.

A systematic review by Umbehr et al (2013) investigated the use of $^{11}$C-choline and $^{18}$F-FCH-PET and $^{18}$F-FCH-PET/CT in staging and restaging of prostate cancer. The literature search, conducted through July 2012, identified 10 studies (total N=637 patients) to be included in the initial prostate cancer staging analysis; pooled sensitivity was 84% (95% CI, 68% to 93%) and specificity was 79% (95% CI, 53% to 93%). Twelve studies (total N=1055 patients) were included in the restaging analysis; pooled sensitivity and specificity were 85% (95% CI, 79% to 89%) and 88% (95% CI, 73% to 95%), respectively.

Mohsen et al (2013) conducted a systematic review of 23 studies on $^{11}$C-acetate PET imaging for the detection of primary or recurrent prostate cancer. For detection of recurrence, 14 studies were included in a meta-analysis. The pooled sensitivity was 68% (95% CI, 63% to 73%) and pooled specificity was 93% (95% CI, 83% to 98%). Study quality was considered poor, and low sensitivities and specificities appear to limit the validity of $^{11}$C-acetate imaging in prostate cancer. Currently, $^{11}$C-acetate is not approved by the Food and Drug Administration.

Other systematic reviews, including those by Sandgren et al (2017) and Albisinni et al (2018), have also reported that $^{11}$C-choline PET/CT exhibits high sensitivity and specificity estimates in the staging and restaging of prostate cancer.

Both the NCCN report conducted by Podoloff et al (2009) and the AHRQ review by Ospina et al (2008) found the evidence insufficient to support the use of PET for any indication in patients with prostate cancer. Reports
showed significant overlap between benign prostatic hyperplasia, malignant tumor, local recurrence, and postoperative scarring. PET may have limited sensitivity in detecting distant metastatic disease. The AHRQ report identified only 4 studies of PET for the indications of restaging and recurrence, none of which addressed the effect of PET on management decisions.

**Observational Studies**

Bach-Gansmo et al (2017) conducted a retrospective study assessing the use of anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) in the staging of biochemically recurrent prostate cancer. The reference standard was histologic confirmation, which was blinded to PET findings. Detection rates were calculated for the prostate, extra-prostate, and whole body at quartiles of PSA levels. At the highest quartile (>6.0 ng/mL), detection rates were 69%, 69%, and 86% for the prostate, extra-prostate, and whole body scans, respectively. For PSA levels from 2.0 to 6.0 ng/mL, detection rates were 50%, 46%, and 75%, respectively. For PSA levels from 0.8 to 2.0 ng/mL, detection rates were 22%, 45%, and 59%, respectively. For the lowest quartile (≤0.8 ng/mL), detection rates were 14%, 31%, and 41%, respectively. (Note that BCBSA extrapolated detection rates from a graphic.)

**Prostate Cancer Management**

Andriole et al (2018) presented results from the LOCATE trial. The study population consisted of 213 men who had undergone curative intent treatment of histologically confirmed prostate cancer and were suspected to have recurrence based on rising PSA levels. Fluciclovine-avid lesions were detected in 122 (57%) patients. Compared with management plans specified by the treating physicians prior to the PET scans, 126 (59%) patients had a change in management. The most frequent change in management was from salvage or noncurative systemic therapy to watchful waiting (n=32) and from noncurative systemic therapy to salvage therapy (n=30).

Akin-Akintayo et al (2017) evaluated the role of fluciclovine PET/CT in the management of post-prostatectomy patients with PSA failure being considered for salvage radiotherapy. Forty-two patients who were initially planning radiotherapy due to post-prostatectomy PSA failure underwent fluciclovine PET/CT. Based on the PET/CT results, 17 (40.5%) patients changed a decision relating to the radiotherapy; 2 patients received hormonal therapy rather than radiotherapy when fluciclovine showed extrapelvic disease; 11 patients increased the radiotherapy field from prostate bed only to prostate plus pelvis, and 4 patients reduced the radiotherapy fields from prostate plus pelvis to prostate bed only.

The European Association of Urology’s guidelines (2014) for prostate cancer have indicated that 11C-choline PET/CT has limited value unless PSA levels exceed 1.0 ng/mL. In meta-analysis of 14 studies (total N=1667 patients) of radiolabeled choline PET/CT for restaging prostate cancer, Treglia et al (2014) reported a maximum pooled sensitivity of 77% (95% CI, 71% to 82%) in patients with a PSA velocity of greater than 2 ng/mL per year. Pooled sensitivity was lower for patients with a PSA velocity of less than 2 ng/mL per year or with a PSA level doubling time of 6 months or less. In meta-analysis of 11 studies (total N=609 patients) of radiolabeled choline PET/CT for staging or restaging prostate cancer, von Eyben et al (2014) reported a
pooled sensitivity and specificity of 59% (95% CI, 51% to 66%) and 92% (95% CI, 89% to 94%), respectively. Pooled positive predictive value and NPV were 70% and 85%, respectively.

Guidelines

American College of Radiology
ACR Appropriateness Criteria on posttreatment follow-up of patients with prostate cancer have stated that PET and PET/CT using $^{11}$C-choline or $^{18}$F-fluoride radiotracers is usually appropriate for patients with a clinical concern for residual or recurrent disease following radical prostatectomy, nonsurgical treatments, or systemic therapy.

National Comprehensive Cancer Network
Current NCCN guidelines for prostate cancer (v.3.2018) indicate that $^{11}$C-choline PET may be considered for evaluating biochemical failure after primary treatment (ie, radiotherapy or radical prostatectomy). To evaluate progression, $^{11}$C-choline PET/CT or $^{18}$F-fluciclovine PET/CT may be considered for soft tissue assessment and $^{18}$F-sodium fluoride PET/CT may be considered for bone assessment. The guidelines note that $^{18}$F-sodium fluoride PET/CT has greater sensitivity but lower specificity than standard bone scan imaging. FDG-PET should not be used routinely for initial assessment or in other settings, due to limited evidence of clinical utility.

Subsection Summary: $^{11}$C-Choline PET, $^{11}$C-Choline PET/CT, $^{18}$F-Fluciclovine PET, and $^{18}$F-Fluciclovine PET/CT for Prostate Cancer
The choice of radiotracer affects the sensitivity and specificity of the scans. Evidence for the use of $^{11}$C-choline PET and $^{11}$C-choline PET/CT for diagnosis, staging, and restaging of prostate cancer, consists of meta-analyses, which have shown that the use of $^{11}$C-choline results in the highest sensitivities and specificities compared with other radiotracers. Evidence for the use of fluciclovine PET/CT for staging, restaging, and management of prostate cancer consists of observational studies. The studies reported increased detection with fluciclovine PET/CT; however, detection rates decreased as PSA levels decreased. Two prospective studies reported that a majority of management decisions were changed based on fluciclovine PET results among men with suspected recurrence. Further study is needed to compare PET and PET/CT with other imaging techniques, such as MRI and radionuclide bone scan. The evidence supports the use of $^{11}$C-choline PET and PET/CT and $^{18}$F-fluciclovine PET and PET/CT for the diagnosis, staging, and restaging of prostate cancer.

The evidence does not support the use of $^{11}$C-choline PET and PET/CT and $^{18}$F-fluciclovine PET and PET/CT for surveillance of prostate cancer.

$^{68}$Ga-PET and $^{68}$Ga-PET/CT
**Systematic Reviews**

The Albisinni et al (2018) review, discussed in the ¹¹C-choline PET/CT section, and a systematic review by Eissa et al (2018) noted that an advantage of using ⁶⁸Ga prostate-specific membrane antigen (PSMA) PET compared with other radiotracers is the potential to detect local and distant recurrences in patients with lower PSA levels (<0.5 ng/ml).

A systematic review by Perera et al (2016) calculated the sensitivity, specificity, and predictive value of ⁶⁸Ga-PSMA PET in advanced prostate cancer. The literature search, conducted through April 2016, identified 16 studies (total N=1309 patients) for inclusion, though only 11 studies reported histopathologic correlations. Four studies provided data for calculating the predictive ability of ⁶⁸Ga-PSMA PET: a pooled sensitivity of 86% (95% CI, 37% to 98%) and a pooled specificity PSMA of 86% (95% CI, 3% to 100%). The other studies assessed ⁶⁸Ga-PSMA PET positivity by the amount of radiopharmaceutical injected and for detection of primary and metastatic lesions. Reviewers noted that these analyses were exploratory, because most studies were small, retrospective, from single institutions, and had heterogeneous patient cohorts.

**Guidelines**

The current NCCN guidelines for prostate cancer (v.3.2018) note that ⁶⁸Ga-PSMA PET “may provide better detection of recurrences at lower PSA levels than reported for FDA-approved imaging agents.” However, NCCN guidelines consider ⁶⁸Ga-PSMA investigational at this time.

**Subsection Summary: ⁶⁸Ga-PET and ⁶⁸Ga-PET/CT for Prostate Cancer**

Evidence for the use of ⁶⁸Ga-PET and ⁶⁸Ga-PET/CT consists of a systematic review of small single-institution studies. The confidence intervals of the sensitivity and specificity are wide, indicating uncertainty in the results. The evidence does not support the use of ⁶⁸Ga-PET and ⁶⁸Ga-PET/CT for the diagnosis, staging and restaging, and surveillance of prostate cancer.

**Testicular Cancer**

**Systematic Reviews**

An AHRQ technology assessment conducted by Ospina et al (2008) and studies evaluating residual masses in patients after chemotherapy for seminoma have supported the use of PET.

The AHRQ systematic review conducted by Matchar et al (2004) found 1 prospective study and 4 retrospective studies that generally showed higher sensitivity and specificity for PET compared with CT. However, these studies were small in size and failed to report separate results for patients with and without seminoma. Studies also failed to report separate results by clinical stage of the disease.

In addition, studies on PET’s ability to discriminate viable tumor and necrosis or fibrosis after treatment of testicular cancer were flawed in 2 main ways. First, most studies did not compare the diagnostic accuracy of PET with other imaging modalities. Second, studies that did compare PET and CT did not state a clear threshold for a positive CT test, making study results difficult to interpret. Therefore, it is uncertain whether
the use of PET leads to different patient management decisions and health outcomes compared with other imaging modalities.

**Guidelines**
Current NCCN guidelines for testicular cancer (v.2.2018) support the use of PET to evaluate residual masses that are greater than 3 cm following primary treatment with chemotherapy (at ≥6 weeks posttreatment). If a PET scan is negative, surveillance is recommended. If a PET scan is positive, resection or biopsy of residual mass is recommended. The guidelines warn that there is "limited predictive value for PET/CT scan for residual masses." PET is not recommended for nonseminoma patients.

**Section Summary: Testicular Cancer**
Evidence for the use of PET or PET/CT in patients with testicular cancer consists of an AHRQ systematic review of small studies. Results showed that PET or PET/CT can be useful in evaluating residual masses following chemotherapy for seminoma. There is no evidence supporting the use of PET or PET/CT in nonseminoma patients. The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis and staging and restaging of testicular cancer.

The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of testicular cancer.

**THYROID CANCER**

**Systematic Reviews**

**Differentiated**
Schutz et al (2018) conducted a systematic review and meta-analysis of 29 prospective studies (22 differentiated, 7 medullary) investigating the staging, restaging, and recurrence of thyroid cancer. Meta-analyses showed higher sensitivity and specificity with PET compared with conventional imaging.

Haslerud et al (2016) conducted a systematic review of studies using FDG-PET to detect recurrent differentiated thyroid cancer in patients who had undergone ablative therapy. The literature search, conducted through December 2014, identified 34 studies (total N=2639 patients) for inclusion: 17 using FDG-PET/CT, 11 using FDG-PET, and 6 using both methods. Study quality was assessed using the QUADAS tool. Pooled sensitivity and specificity for FDG-PET/CT were 80% (95% CI, 74% to 86%) and 76% (95% CI, 63% to 85%), respectively. Pooled sensitivity and specificity for FDG-PET alone were 77% (95% CI, 63% to 86%) and 76% (95% CI, 60% to 87%), respectively. Combining all 34 studies in the meta-analysis resulted in a pooled sensitivity and specificity of 79% (95% CI, 74% to 84%) and 79% (95% CI, 71% to 85%), respectively.

The NCCN report conducted by Podoloff et al (2009) showed that PET can localize recurrent disease when other imaging tests are negative. Additionally, PET was found to be prognostic in this setting: More metabolically active lesions on PET were strongly correlated with reduced survival.

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Guidelines
Current NCCN guidelines for thyroid carcinoma continue to support the use of FDG-PET/CT in thyroid cancer evaluations, such as when iodine-131 imaging is negative and stimulated thyroglobulin is greater than 2 to 5 ng/mL.

Medullary
A meta-analysis of studies on detecting recurrent or metastatic medullary thyroid carcinoma was conducted by Cheng et al (2012). The literature search, conducted through December 2010, identified 15 studies to be included in the meta-analysis: 8 used FDG-PET and 7 used FDG-PET/CT. The pooled sensitivity for FDG-PET alone in detecting recurrent or metastatic medullary thyroid cancer was 68% (95% CI, 64% to 72%). The pooled sensitivity for FDG-PET/CT was 69% (95% CI, 64% to 74%).

Guidelines
Current NCCN guidelines for medullary thyroid cancer (v.1.2018) recommend contrast-enhanced CT with or without PET at 2 to 3 months postoperative surveillance. Additionally, PET/CT may be considered if recurrent disease is suspected.

Section Summary: Thyroid Cancer
Evidence for the use of PET and PET/CT to diagnose recurrent differentiated and medullary thyroid cancer consists of systematic reviews and meta-analyses. Pooled sensitivity and specificity for FDG-PET and FDG-PET/CT in detecting recurrent differentiated thyroid cancer were comparable, ranging from 76% to 80%. Pooled sensitivity for both PET and PET/CT in detecting recurrent medullary thyroid cancer were also comparable (68% to 69%). The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis and staging and restaging of thyroid cancer.

The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of thyroid cancer.

CANCER OF UNKNOWN PRIMARY
Burglin et al (2017) conducted a systematic review and meta-analysis on the use of PET/CT for the detection of the primary tumor in patients with extra cervical metastases. The literature search identified 20 studies (total N=1942 patients) published between 2005 and 2016 for inclusion. The QUADAS tool was used to assess the risk of bias. In regard to patient selection and reference standard, the risk of bias was low; however, the risk of bias was high or unclear for most studies in regard to flow and timing of the index test. The pooled detection rate was 41% (95% CI, 39% to 43%), with large heterogeneity among the studies.

A TEC Assessment (2002) concluded that FDG-PET met TEC criteria for the workup and management of patients with cancers of unknown primary and a single site of metastatic disease. Specifically, local or regional therapy might be offered to these patients. In this setting, PET scanning might be used to verify the absence of disseminated disease.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Regarding this application, the TEC Assessment identified 4 reports of 47 total patients referred for imaging of a single known metastatic site from a cancer of unknown primary. In 13 (28%) of these patients, PET scanning identified previously undetected metastases that were confirmed by biopsy. Therefore, the use of PET was found to contribute to optimal decision making regarding the appropriateness of local or regional therapy.

No evidence was identified that evaluated the use of FDG-PET for surveillance of patients with cancer of unknown primary.

Section Summary: Cancer of Unknown Primary
The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis, staging and restaging of cancer of unknown primary.

CANCER SURVEILLANCE
Clinical utility of PET scanning in surveillance (ie, in performing follow-up PET scans in asymptomatic patients to detect early disease recurrence) is not well-studied. (For this evidence review, a scan is considered a surveillance scan if performed more than 6 months after therapy [but 12 months for lymphoma].) The NCCN report by Podoloff et al (2009) stated that “PET as a surveillance tool should only be used in clinical trials.” Additionally, NCCN guidelines for various malignancies often note that PET scans are not recommended in asymptomatic patients. For example, current NCCN guidelines for breast cancer comment that PET scans (as well as many other imaging modalities) provide no advantage in survival or ability to palliate recurrent disease and are not recommended.

OTHER ONCOLOGIC APPLICATIONS
There are inadequate scientific data to permit conclusions on the role of PET scanning in other malignancies.

References

Policy History
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019
10/18/2001 Medical Policy Committee review
11/12/2001 Managed Care Advisory Council approval
06/24/2002 Format revision. No substance change to policy
10/05/2004 Medical Director review
12/14/2004 Medical Policy Committee review. Format revision. Coverage eligibility criteria for Unknown Primary and Thyroid Cancer added.
01/31/2005 Managed Care Advisory Council approval

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

07/19/2005   Omission corrected: Melanoma, Staging and Restaging for the purpose of detecting disease was corrected to reflect policy intent: “for the purpose of detecting residual disease”.
10/10/2005   Medical Director review
10/27/2005   Quality Care Advisory Council approval
12/20/2005   Medical Policy Committee review. Coverage eligibility coverage changes: The terms Staging and Restaging have been substituted for “differentiation” for Colorectal Cancer indications. Use of PET in the restaging of colorectal cancer was added; “To detect recurrence of colorectal cancer in patients with rising CEA levels and/or in patients who present with signs and symptoms of recurrence”.
12/20/2005   Medical Policy Committee review. Coverage eligibility coverage changes: The terms Staging and Restaging have been substituted for “differentiation” for Colorectal Cancer indications. Use of PET in the restaging of colorectal cancer was added; “To detect recurrence of colorectal cancer in patients with rising CEA levels and/or in patients who present with signs and symptoms of recurrence”.
12/20/2005   Medical Policy Committee approval. Coverage eligibility updated:
Breast Cancer changed from:
  Diagnosis
  o in clinical situations in which the PET results may assist in avoiding an invasive diagnostic procedure, or in which the PET results may assist in determining the optimal anatomical location to perform an invasive diagnostic procedure. In general, for most solid tumors, a tissue diagnosis is made prior to the performance of PET scanning. PET scans following a tissue diagnosis are performed for the purpose of staging, not diagnosis.
  Staging and/or Restaging
  o in clinical situations in which the stage of the cancer remains in doubt after completion of standard diagnostic workup or for restaging after the completion of treatment; or
  o for the purpose of detecting residual disease; or
  o for detecting suspected recurrence; or
  o to determine the extent of a known recurrence.
  Changed To:
  Staging (before any treatment)
  o As an adjunct to standard imaging modalities in the staging of breast cancer with distant metastases, excluding staging of axillary lymph nodes.
  o Restaging (after treatment has been completed)
  o As an adjunct to standard imaging in the restaging of loco-regional recurrence or metastases
Treatment Response Monitoring
  o For women with locally advanced and metastatic breast cancer, when a change in therapy is anticipated.
Colorectal Cancer changed from:
  Diagnosis
  o as a technique to detect and assess resectability of hepatic or extrahepatic metastases of colorectal cancer.

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

Restaging
- to assess the presence of scarring versus local bowel recurrence in patients with previously resected colorectal cancer.
- to detect recurrence of colorectal cancer in patients with rising CEA levels and/or in patients who present with signs and symptoms of recurrence.

Changed To:
Diagnosis—when PET results may assist in
- Avoiding an invasive diagnostic procedure, or
- Determining the optimal anatomical location to perform an invasive diagnostic procedure
- The diagnosis has not been confirmed by tissue biopsy

Staging
- The cancer stage remains in doubt after completion of a standard diagnostic workup.
- PET could potentially replace one or more conventional imaging studies, when it is expected that conventional study information is insufficient for the clinical management of the patient, or
- Clinical management would differ depending on the cancer stage

Restaging for the purpose of
- Detecting residual disease (after completion of treatment), or
- Detecting suspected recurrence (ex: rising CEA levels; clinical signs/symptoms suspicious for recurrence)
- Determination of the extent of known recurrence

Potentially replacing one or more conventional imaging studies, when it is expected that information from these studies will be insufficient for clinical management of the patient.

©2019 Blue Cross and Blue Shield of Louisiana
Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Positron Emission Tomography (PET) Oncology Applications

Policy # 00105
Original Effective Date: 01/28/2002
Current Effective Date: 06/01/2019

06/25/2013 Medical Policy Implementation Committee approval. Added coverage for staging and restaging of multiple myeloma.
05/01/2014 Medical Policy Committee review
05/21/2014 Medical Policy Implementation Committee approval. Deleted “when suspicion of disease is high and other imaging is inconclusive” from the Eligible for Coverage statements for breast cancer staging and restaging.
06/25/2015 Medical Policy Committee approval
06/30/2016 Medical Policy Committee approval
07/20/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
09/07/2017 Medical Policy Committee approval
09/20/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/05/2017 Medical Policy Committee approval
10/18/2017 Medical Policy Implementation Committee approval. Additional details added to policy statements. The following statements were changed to eligible for coverage: restaging of Ewing sarcoma and osteosarcoma for bone cancer, staging or restaging of brain cancer; restaging in the evaluation of response to treatment in head and neck cancer; restaging of esophageal cancer for determining response to preoperative induction therapy, and restaging when used with testing with 11C-choline for evaluating response to primary treatment in prostate cancer. Three additional indications were added to be eligible for coverage (endometrial cancer, gastric cancer and renal cell carcinoma).
11/08/2018 Medical Policy Implementation Committee approval
11/21/2018 Medical Policy Implementation Committee approval. Added a Bladder Cancer section to track BCBSA. “Bone Cancer” section changed to read “Bone Sarcoma” to align with BCBSA. For breast cancer staging and restaging, added “...when suspicion of disease is high and other imaging (e.g. CT, MRI, bone scan) is inconclusive,” to align with BCBSA and examples from AIM Guidelines. Incorporated BCBSA and AIM verbiage into Cervical Cancer section. For the Colorectal Cancer section, removed Diagnosis, edited Staging to align with AIM Guidelines, and edited Restaging based on BCBSA and AIM Guidelines. For the Esophageal Cancer section, combined 2 bullets into 1 in Staging to align with BCBSA and AIM Guidelines; combined bullets 1 and 3 in Restaging for a total of 2 bullets to align with AIM Guidelines. For the Lung Cancer section, removed 3rd bullet from Diagnosis and the 1st bullet from Staging; added “In the staging of small-cell lung cancer if limited stage is suspected based on standard imaging” may be eligible for coverage. Added a Note that...
limited stage SCLC is limited to the ipsilateral hemithorax and regional or mediastinal lymph nodes and can be encompassed in a safe radiotherapy field; for Restaging, edited bullets by deleting what was the 2nd bullet and combined it with the 1st bullet and added NSCLC to new 2nd bullet; changed investigational statement for Staging to track BCBSA. For the Lymphoma section, removed Diagnosis and removed what was the 1st bullet from Restaging since it was redundant. For the Melanoma section, removed Diagnosis and added “for advanced disease (stage III and IV)” to Staging and Restaging bullets to align with BCBSA; removed “restaging” from the investigational statement for PET scanning in managing stage 0, I, or II melanoma. For the Multiple Melanoma section, edited Staging and Restaging to incorporate BCBSA and AIM Guidelines and deleted 2nd bullet from Restaging. For the Neuroendocrine Tumors section, coverage changed from investigational to eligible for coverage; Neuroendocrine Tumors section created with Staging and Restaging as eligible for coverage and added an investigational statement; section created for Neuroendocrine Tumors with Diagnosis, Staging and Restaging as eligible for coverage and for an Investigational statement. All newly proposed AIM Guidelines criteria for Ga-PET were adopted for this section, in place of more limited BCBSA criteria. For the Ovarian Cancer section, Diagnosis and Staging removed, Restaging simplified into one statement; investigational statement aligns with BCBSA’s. Created a separate section for Penile Cancer as investigational with coverage eligibility unchanged. For the Prostate Cancer section, removed Staging; replaced the Restaging section to be consistent with AIM Guidelines and NCCN. Created a separate section for Renal Cell Carcinoma as investigational with coverage eligibility unchanged. For the Soft Tissue Sarcoma section, PET for evaluating response to imatinib and other treatments for gastrointestinal stromal tumors was changed from investigational to eligible for coverage to align with BCBSA. For the Thyroid Cancer section, removed Diagnosis and added “or poorly differentiated” to the investigational statement. Removed the Other Oncologic Applications section, since new sections for Neuroendocrine Tumors, Penile Cancer and Renal Cell Cancer have been created.

03/07/2019 Medical Policy Committee review

Next Scheduled Review Date: 03/2020

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2018 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is

©2019 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Positron Emission Tomography (PET) Oncology Applications

Policy #  00105
Original Effective Date:  01/28/2002
Current Effective Date:  06/01/2019

not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>78811, 78812, 78813, 78814, 78815, 78816</td>
</tr>
<tr>
<td>HCPCS</td>
<td>A9515, A9526, A9552, A9580, A9587, A9588, A9598, G0219, G0235, G0252</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>C00.0-C96.9</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or "Medical Necessity") - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.